Optimized mRNA encoding Cas9 for use in LNPs

By developing a method for encapsulating small molecule RNA with lipid nanoparticles containing specific lipids, the problem of difficulty in delivering large bioactive agents in cells is solved, and efficient and stable genome editing and delivery effects are achieved.

CN113710799BActive Publication Date: 2024-11-12CRISPR THERAPEUTICS AG +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980090537.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-11-28
Filing Date
2019-11-26
Publication Date
2024-11-12
Estimated Expiration
2039-11-26

AI Technical Summary

Technical Problem

The prior art is difficult to efficiently deliver large bioactive agents such as site-specific endonucleases to target cells, especially due to the instability and high charge of these molecules in cells or plasma, which lead to difficulties in delivery across the cell membrane.

Method used

A lipid nanoparticle (LNP)-based composition has been developed, containing nucleic acid molecules of about 3.8 kb or less in length, combining amino lipids, ionizable lipids, neutral lipids, PEG lipids, auxiliary lipids and Cholesterol or its derivatives are used to encapsulate mRNA encoding site-specific endonucleases, improving delivery efficiency and stability.

Benefits of technology

It improves the efficiency of genome editing and the stability of the composition, enhances the delivery ability to target cells, reduces the rate of reduction of functional performance, and improves the feasibility of drug manufacturing and application due to the large particle diameter.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113710799B_ABST
    Figure CN113710799B_ABST
Patent Text Reader

Abstract

The present disclosure generally relates to novel lipid nanoparticle (LNP)-based compositions that can be used, for example, to deliver site-specific endonucleases or nucleic acid molecules encoding the site-specific endonucleases to target cells. Some embodiments of the present disclosure relate to compositions and methods for editing the genome of a cell, comprising contacting the cell with an LNP composition as described herein.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of priority to U.S. Provisional Patent Application Serial No. 62 / 772,278, filed on November 28, 2018, which is expressly incorporated herein by reference in its entirety (including any drawings).

[0003] Incorporation of Sequence Listing

[0004] The material in the attached sequence listing is hereby incorporated by reference into this application. The attached sequence listing text file named 052984-536001WO_SequenceListing_ST25.txt was created on November 21, 2019, and is 229,434 bytes. Technical Field

[0005] The present disclosure relates to compositions and methods for delivering molecules (e.g., nucleic acids) to target cells. Such particles can be used, for example, to deliver components for genome editing. Specifically, the application relates to RNA-lipid nanoparticle compositions. Background Art

[0006] Recent advances in genome sequencing technology and analytical methods have significantly accelerated the ability to identify and map genetic elements associated with different ranges of biological functions and diseases. Precise genome targeting technologies are needed to enable reverse engineering of causal genetic variations by allowing selective interference with individual genetic elements, as well as to advance synthetic biology, biotechnology applications, and medical applications. In recent years, targeted genome editing technologies using engineered nucleases have progressed from niche technologies to advanced methods used by many biological researchers. This adoption has been greatly promoted by the emergence of a new class of site-specific endonucleases (including designer zinc fingers, transcription activator-like effectors (TALEs), homing meganucleases), and the development of clustered regularly interspaced short palindromic repeats (CRISPR) technology.

[0007] However, delivery of large bioactive agents (such as site-specific endonucleases or nucleic acids encoding these site-specific endonucleases) to target cells or tissues is often hindered by the difficulty of these agents to reach target living cells or tissues. Specifically, the transportation of many bioactive agents to living cells may be limited by the membrane system of the cell. In fact, it has been widely reported that a class of bioactive agents that are particularly difficult to deliver to cells are large biomolecules, including proteins, therapeutic agents based on nucleic acids, and derivatives thereof. Some nucleic acids and proteins are stable only in a limited duration in cells or blood plasma, and are sometimes highly charged, which can complicate the delivery across cell membranes.

[0008] Therefore, there is a need for compositions and methods for delivering site-specific endonucleases to target living cells. In particular, there is a need for compositions and methods that can improve the stability of such biomolecules and allow such biomolecules to be efficiently delivered to living cells and tissues of particular interest. Summary of the invention

[0009] This section provides a general summary of the disclosure, and is not a comprehensive disclosure of its full scope or all of its features.

[0010] The present disclosure relates to novel lipid nanoparticle (LNP) based compositions comprising nucleic acid molecules of about 3.8 kb or less in length (referred to herein as "smLNP compositions") that can be used to deliver nucleic acids encoding site-specific endonucleases to target cells. In some embodiments, the present disclosure provides methods for editing the genome of a cell, comprising contacting such a cell with an LNP composition as described herein. In some embodiments, the present disclosure provides methods for treating a disease using the compositions and / or methods described herein.

[0011] In one aspect, some embodiments of the present disclosure relate to a lipid-based nanoparticle (LNP) composition, the lipid-based nanoparticle composition comprising: (a) a nucleic acid molecule containing a nucleotide sequence encoding a site-specific endonuclease; and (b) one or more lipid moieties, the one or more lipid moieties being selected from the group consisting of amino lipids, ionizable lipids, neutral lipids, PEG lipids, auxiliary lipids, and cholesterol or cholesterol derivatives; wherein the length of the nucleic acid molecule is about 3.8 kb or less. This LNP composition is hereinafter referred to as a "smLNP composition".

[0012] The implementation of the embodiment of the smLNP compositions of the present disclosure may include one or more of the following features. In certain embodiments, the length of the nucleic acid molecule is about 3.7kb or less. In certain embodiments, the length of the nucleic acid molecule is about 3.5kb or less. In certain embodiments, the nucleic acid molecule is messenger RNA (mRNA). In certain embodiments, the nucleotide sequence encoding the site-specific endonuclease is operably connected to at least one other nucleotide sequence. In certain embodiments, the at least one other nucleotide sequence includes a non-translated terminal region (UTR), a total Kozak (Kozak) signal, a nucleotide sequence encoding a nuclear localization signal (NLS), a nucleotide sequence encoding a joint peptide, a nucleotide sequence encoding a tag peptide, or any combination thereof. In certain embodiments, the nuclear localization signal (NLS) includes a nucleoplasmin NLS or a SV40 NLS.

[0013] In some embodiments of the present disclosure, the site-specific endonuclease is a Cas9 protein or a functional derivative thereof. In some embodiments, the site-specific endonuclease comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO 5, and SEQ ID NO: 6. In some embodiments, the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.

[0014] In some embodiments of the present disclosure, the nucleotide sequence encoding the site-specific endonuclease is codon optimized for expression in a host cell. In some embodiments, the host cell is a mammalian cell. In some embodiments, the mammalian cell is a human cell, a mouse cell, or a non-human primate cell.

[0015] In some embodiments, the smLNP compositions of the present disclosure further comprise one or more additional components of a CRISPR system. In some embodiments, the one or more additional components of the CRISPR system include a guide RNA (gRNA) or a nucleic acid molecule encoding the gRNA.

[0016] In some embodiments, the smLNPs of the smLNP compositions disclosed herein comprise an amino lipid. In some embodiments, the amino lipid comprises C12-200.

[0017] In some embodiments, the smLNPs of the smLNP compositions disclosed herein comprise a structural lipid. In some embodiments, the structural lipid comprises cholesterol.

[0018] In some embodiments, the smLNPs of the smLNP compositions disclosed herein comprise a helper lipid. In some embodiments, the helper lipid comprises DOPE.

[0019] In some embodiments, the smLNPs of the smLNP compositions disclosed herein comprise PEG lipids. In some embodiments, the PEG lipid comprises PEG-DMPE.

[0020] In some embodiments, the smLNPs of the smLNP compositions disclosed herein comprise one or more of C12-200, cholesterol, DOPE, and PEG-DMPE. In some embodiments, the smLNPs comprise C12-200, cholesterol, DOPE, and PEG-DMPE.

[0021] In some embodiments, the smLNPs of the smLNP compositions disclosed herein have a lower rate of change of physicochemical properties compared to the LNPs of a reference LNP composition, the reference LNP composition comprising a nucleic acid molecule containing a nucleotide sequence encoding a site-specific endonuclease, wherein the nucleic acid molecule is greater than about 4 kb. In some embodiments, the smLNPs of the smLNP compositions have a rate of change of physicochemical properties that is at least about 5% less than the corresponding rate of the LNPs of the reference LNP composition. In some embodiments, the smLNP compositions have a lower rate of decrease in functional performance compared to the rate of decrease in functional performance of the reference LNP composition, the reference LNP composition comprising a nucleic acid molecule containing a nucleotide sequence encoding a site-specific endonuclease, wherein the nucleic acid molecule is greater than about 4 kb. In some embodiments, the smLNP compositions have a rate of decrease in functional performance that is at least about 5% less than the corresponding rate of the reference LNP composition.

[0022] In some embodiments, the smLNPs of the smLNP compositions disclosed herein have an average particle diameter greater than the average particle diameter of the LNPs of a reference LNP composition, the reference LNP composition comprising a nucleic acid molecule comprising a nucleotide sequence encoding a site-specific endonuclease, wherein the nucleic acid molecule is greater than about 4.4 kb. In some embodiments, the smLNPs of the smLNP composition have an average particle diameter that is at least about 10% greater than the average particle diameter of the LNPs in the reference LNP composition (such as at least about 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, or any one of greater). In some embodiments of the present disclosure, the reference LNP composition comprises a nucleic acid molecule having a length of about 4.4 kb or more.

[0023] In one aspect, some embodiments of the present disclosure relate to a method for delivering a nucleic acid molecule into a cell, the method comprising contacting the cell with a smLNP composition as disclosed herein, wherein the smLNP composition comprises the nucleic acid molecule.

[0024] In one aspect, some embodiments of the present disclosure relate to a method for editing the genome of a cell, the method comprising providing to the cell a smLNP composition as disclosed herein.

[0025] Implementations of embodiments of the methods disclosed herein may include one or more of the following features. In some embodiments, the editing efficiency of the smLNP composition is greater than the editing efficiency of a reference LNP composition, the reference LNP composition comprising a nucleic acid molecule containing a nucleotide sequence encoding a site-specific endonuclease, wherein the nucleic acid molecule is greater than about 4kb. In some embodiments, the editing efficiency of the smLNP composition is at least 5% greater than the editing efficiency of the reference LNP composition. In some embodiments of the methods disclosed herein, the cell is a mammalian cell. In some embodiments, the mammalian cell is a human cell, a mouse cell, or a non-human primate cell.

[0026] The foregoing summary is illustrative only and is not intended to be limiting in any way. In addition to the illustrative embodiments and features described herein, further aspects, embodiments, objects, and features of the present disclosure will become fully apparent from the drawings and detailed description, and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figures 1A-1E Graphically summarized are the results of experiments performed to characterize lipid-based nanoparticles (LNPs) showing the size difference between LNPs containing SpCas9 (i.e., reference LNPs) and smCas9 (i.e., smLNPs). Figure 1A is a bar graph showing the particle size of LNPs as determined by dynamic light scattering (DLS). Figure 1B is a bar graph showing the heterogeneity of a mixed LNP population as characterized by the polydispersity index (PDI). Figure 1C is a bar graph showing the size of LNPs as determined by nanoparticle tracking analysis (NTA). Figure 1D is a bar graph showing the mRNA encapsulation efficiency of LNPs. Figure 1E It is a graph showing the distribution of the ratio of particles to RNA as a function of particle size.

[0028] Figure 2 The results of experiments conducted to evaluate the editing efficiency of various site-specific endonucleases delivered to murine cells using various exemplary mRNA-LNP compositions according to some embodiments of the present disclosure (e.g., smLNP compositions) are graphically summarized. In these experiments, in MessengerMAX TMAfter transfection, the endogenous albumin locus in murine Hepa 1-6 cells was targeted by several endonucleases, including the reference Cas9 protein from Streptococcus pyogenes (SpCas9), and a small Cas9 variant (smCas9); Gib11Spa3, Gib11Spa1, Slu, F8, E2, and P2H12.

[0029] Figure 3 The results of experiments performed to demonstrate that smLNP compositions containing Gib11Spa1 smCas9 or Gib11Spa3 smCas9 variants are more potent than LNP compositions containing SpCas9 in vivo when delivered into cells using mRNA-LNP compositions according to some embodiments of the present disclosure are graphically summarized.

[0030] Figure 4 smLNPs containing mRNA encoding smCas9GST3-K, smCas9 GST3, smCas9 GST3-v1, smCas9 GST1-v1, or LNPs containing reference SpCas9 when administered intravenously in C57BL / 6 mice. The target locus for these experiments was the albumin locus. Each point represents a whole liver TIDE analysis of one animal. These results demonstrate that all of the aforementioned smCas9 variants perform better than SpCas9 when delivered in mRNA-LNP formulations according to the present disclosure.

[0031] Figure 5 smLNPs containing mRNA encoding smCas9 GST3-v1, smCas9 GST1-v1, or LNPs containing reference mRNA encoding SpCas9 when unmodified or modified with N1-methyl-pseudouridine bases are bar graphs showing the insertion and deletion (INDEL) efficiency of LNPs containing mRNA encoding smCas9 GST3-v1, smCas9 GST1-v1, or reference mRNA encoding SpCas9. In this experiment, mRNA-LNPs were administered intravenously in C57BL / 6 mice at a single dose of 2 mpk. These results demonstrate that (i) N1-methyl-pseudouridine modification improves the performance of SpCas9, but not the performance of GST3-v1 or GST1-v1, and (ii) both unmodified and base-modified mRNAs perform well as smCas9 mRNA-LNPs.

[0032] Figure 6The results of experiments performed to evaluate the physicochemical properties (e.g., stability) of mRNA-LNPs during storage as determined by nanoparticle tracking analysis (NTA) are summarized graphically. In these experiments, the change in mRNA-LNP concentration was determined after 7 days of storage at 2°C-8°C. The figure shows the number of nanoparticles / mL solution, wherein the size of the nanoparticles tested is in the range of from about 30 to about 500nm, and comprises different RNA components. These results demonstrate that, although the particle concentration of SpCas9 is reduced after storage at 2°C-8°C for 7 days, this concentration reduction is not observed for smLNPs containing mRNA encoding each smCas9 variant.

[0033] Figure 7 The results of experiments conducted to evaluate the morphological uniformity of smLNPs according to some exemplary embodiments of the present disclosure are summarized in a pictorial manner. In these experiments, images of LNPs containing SpCas9 mRNA or smCas9Gib11Spa3 mRNA were captured using cryo-transmission electron microscopy (cryo-TEM).

[0034] Figure 8 The results of experiments performed to demonstrate that SmCas9 delivered into cells by mRNA-LNP compositions according to some embodiments of the present disclosure exhibits improved functional stability compared to SpCas9 after 9 days of storage at 2° C.-8° C. are graphically summarized. DETAILED DESCRIPTION

[0035] Provided herein are novel lipid-based nanoparticle (LNP) compositions and methods for delivering CRISPR / Cas gene editing components to cells. Some embodiments of the present disclosure provide compositions and methods for delivering genome editing components in vivo using LNP, and these LNP encapsulate encoding site-specific endonucleases such as small Cas9 (smCas9) endonucleases or mRNAs derived from site-specific endonucleases of one or more smCas9. This mRNA encoding smCas9 or site-specific endonucleases derived from one or more smCas9 is also referred to as "smCas9mRNA" herein. Not bound by any particular theory, it is believed that compared with the corresponding LNP compositions comprising nucleic acid molecules having a length greater than 4.0kb, smaller sizes, such as encapsulated mRNAs less than about 3.8kb in length, confer packaging advantages to smLNPs. As described in more detail below, when compared with corresponding LNPs, the smLNPs according to some embodiments of the present disclosure have shown improved genome editing performance and improved stability.

[0036] It is expected that the compositions and methods disclosed herein have significant commercial and / or clinical applicability, because LNP delivery technology is a key component of many in vivo gene editing methods. Most LNP systems currently in commercial and / or clinical applications carry siRNA payloads, which may be smaller, more stable and / or safer than mRNA payloads. The development of stable LNPs for delivering nucleic acids (such as mRNA) encoding site-specific endonucleases (such as Cas9) that are considered to be large and complex payloads remains a challenge in the art.

[0037] The use of mRNA encoding smCas9 or site-specific endonucleases derived from one or more smCas9 as a payload for LNP delivery can enable LNP technology to be used for in vivo delivery of genome editing nucleases. The key advantages of the compositions and methods disclosed herein include, but are not limited to, (1) LNPs that deliver mRNA encoding smCas9 mRNA or site-specific endonucleases derived from one or more smCas9 have so far been shown to be more potent than LNPs that deliver mRNA encoding SpCas9, and this improved performance may make administration in patients safer; (2) These LNPs are more stable than SpCas9 mRNA-loaded LNPs, so they are more feasible pharmaceutical formulations; and (3) Due to their smaller size, mRNA encoding smCas9 or site-specific endonucleases derived from one or more smCas9 are easier to manufacture than SpCas9 mRNA.

[0038] As described in more detail below, LNP-based delivery systems can be engineered to target hepatocytes in the liver after systemic administration. Encapsulation of smCas9 mRNA into smLNPs is not expected to adversely affect hepatocyte targeting; in fact, smCas9 mRNA LNPs may have improved pharmacokinetics due to enhanced LNP stability compared to SpCas9mRNA LNPs. The key attributes of LNP technology for delivering smCas9 mRNA are the transient nature of endonuclease expression (with endonuclease levels expected to reach baseline 1 week after injection) and the ability to administer multiple LNP doses to titrate to the target effect.

[0039] definition

[0040] Unless otherwise defined, all technical terms, symbols and other scientific terms or expressions used herein are intended to have the meanings commonly understood by those skilled in the art to which this disclosure belongs. In some cases, terms with commonly understood meanings are defined herein for clarity and / or for ease of reference, and such definitions contained herein should not necessarily be interpreted as representing substantial differences from those commonly understood in the art. Many of the techniques and procedures described or referred to herein are fully understood by those skilled in the art and are typically employed using conventional methods.

[0041] Unless the context clearly indicates otherwise, the singular forms "a / an" and "the" include plural referents. For example, the term "a / a cell" includes one / a kind or more / multiple cells, including mixtures thereof. "A and / or B" is used herein to include all of the following alternatives: "A", "B", "A or B", and "A and B".

[0042] As used herein, the term "about" has its ordinary meaning of approximately. If the approximation is not otherwise clear from the context, "about" means within plus or minus 10% of the provided value, or rounded to the nearest significant figure, in all cases including the provided value. If ranges are provided, they include the bounding values.

[0043] It should be understood that aspects and embodiments of the disclosure described herein include "comprising," "consisting of," and "consisting essentially of" aspects and embodiments.

[0044] As used herein, the term "enhanced delivery" means that more (e.g., at least 1.5 times more, at least 2 times more, at least 3 times more, at least 4 times more, at least 5 times more, at least 6 times more, at least 7 times more, at least 8 times more, at least 9 times more, at least 10 times more) nucleic acid molecules are delivered to a target tissue of interest (e.g., mammalian liver) by LNPs as compared to the level of nucleic acid molecules delivered to a target cell or tissue of interest by a control LNP. The level of delivery of LNPs to tissues can be measured by (i) comparing the amount of protein produced in a cell or tissue to the weight of the cell or tissue; (ii) comparing the amount of nucleic acid molecules in a cell or tissue to the weight of the cell or tissue; (iii) comparing the amount of protein produced in a cell or tissue to the amount of total protein in the cell or tissue; (iv) or comparing the amount of polynucleotides in a cell or tissue to the amount of total nucleic acid molecules in the cell or tissue.

[0045] The terms "individual," "subject," "host," and "patient" are used interchangeably herein and refer to any mammalian subject, such as humans (e.g., human subjects), non-human mammals, and non-human primates, particularly humans, for whom diagnosis, treatment, or therapy is desired.

[0046] The terms "nucleic acid molecule" and "polynucleotide" are used interchangeably herein and refer to both RNA and DNA molecules, including nucleic acid molecules comprising cDNA, genomic DNA, synthetic DNA, and DNA or RNA molecules containing nucleic acid analogs. Nucleic acid molecules can be double-stranded or single-stranded (e.g., sense strand or antisense strand). Nucleic acid molecules can contain unconventional or modified nucleotides. As used herein, the terms "polynucleotide sequence" and "nucleic acid sequence" refer interchangeably to the sequence of polynucleotide molecules. The nomenclature of nucleotide bases as set forth in 37 CFR § 1.822 is used herein. In some embodiments of the present disclosure, the nucleic acid molecule of the smLNP composition disclosed herein is messenger RNA (mRNA).

[0047] As used herein, the term "recombinant" nucleic acid molecule refers to a nucleic acid molecule that has been altered by human intervention. As a non-limiting example, cDNA is a recombinant DNA molecule, such as any nucleic acid molecule that has been produced by one or more in vitro polymerase reactions, or to which a linker has been attached, or that has been integrated into a vector (such as a cloning vector or an expression vector). As a non-limiting example, a recombinant nucleic acid molecule: 1) has been synthesized or modified in vitro, for example, using chemical or enzymatic techniques of nucleic acid molecules (e.g., by using chemical nucleic acid synthesis, or by using enzymes for replication, polymerization, exonucleolytic digestion, endonucleolytic digestion, ligation, reverse transcription, transcription, base modification (including, for example, methylation), or recombination (including homologous recombination and site-specific recombination); 2) includes a connected nucleotide sequence that is not connected in nature; 3) has been engineered using molecular cloning techniques so that it lacks one or more nucleotides relative to a naturally occurring nucleic acid molecule sequence; and / or 4) has been manipulated using molecular cloning techniques so that it has one or more sequence changes or rearrangements relative to a naturally occurring nucleic acid sequence.

[0048] As used herein, the term "operably connected" means a physical or functional connection between two or more elements (e.g., a polypeptide sequence or a polynucleotide sequence) that allows them to operate in their intended manner. For example, the operable connection between a polynucleotide of interest and a regulatory sequence (e.g., a promoter) is a functional connection that allows the expression of the polynucleotide of interest. In this sense, the term "operably connected" refers to positioning the regulatory region and the coding sequence to be transcribed so that the regulatory region effectively regulates the transcription or translation of the coding sequence of interest. In some embodiments disclosed herein, the term "operably connected" means such a configuration, wherein the regulatory sequence is placed in an appropriate position relative to the sequence of the encoded polypeptide or functional RNA, so that the control sequence guides or regulates the expression or cellular localization of the mRNA, polypeptide, and / or functional RNA of the encoded polypeptide. Therefore, if the promoter can mediate the transcription of the nucleic acid sequence, the promoter is operably connected to the nucleic acid sequence. The operably connected elements are continuous or discontinuous.

[0049] As used herein, the term "recombination" refers to the process of exchanging genetic information between two polynucleotides. As used herein, "homologous directed repair (HDR)" refers to the DNA repair of a specialized form that occurs during the repair of double-strand breaks in cells, for example. This process requires nucleotide sequence homology, uses a "donor" molecule to provide a template for the repair of a "target" molecule (e.g., a molecule that experiences double-strand breaks), and causes genetic information to be transferred from the donor to the target. If the donor polynucleotide is different from the target molecule, and part or all of the sequence of the donor polynucleotide is incorporated into the target DNA, homologous directed repair may cause a change (e.g., insertion, deletion, mutation) in the target molecule sequence. In certain embodiments, a donor polynucleotide, a part of a donor polynucleotide, a copy of a donor polynucleotide, or a copy of a donor polynucleotide is integrated into the target DNA.

[0050] The term "non-homologous end joining (NHEJ)" refers to the repair of double-strand breaks in DNA by directly joining the broken ends to each other without the need for a homologous template (in contrast to homology-directed repair, which requires homologous sequences to guide the repair). NHEJ often results in the loss (deletion) of nucleotide sequences near the site of the double-strand break.

[0051] "Nuclease" and "endonuclease" are used interchangeably herein to refer to an enzyme with endonucleolytic catalytic activity for polynucleotide cleavage. The term includes site-specific endonucleases such as designer zinc fingers, transcription activator-like effectors (TALEs), homing meganucleases, and site-specific endonucleases of clustered regularly interspaced short palindromic repeats (CRISPR) systems (e.g., such as Cas proteins).

[0052] As used herein, the term "site-specific modifying enzyme" or "RNA binding site-specific modifying enzyme" refers to a polypeptide that binds RNA and targets a specific DNA sequence, such as a Cas9 polypeptide. Site-specific modifying enzymes as described herein are targeted to a specific DNA sequence through the RNA molecule to which it binds. The RNA molecule contains a sequence that binds, hybridizes, or is complementary to a target sequence within the target DNA, thereby targeting the bound polypeptide to a specific position (target sequence) within the target DNA.

[0053] By "cleavage" is meant the breaking of the covalent backbone of a DNA molecule. Cleavage can be initiated by a variety of methods, including but not limited to enzymatic or chemical hydrolysis of phosphodiester bonds. Both single-strand cleavage and double-strand cleavage are possible, and double-strand cleavage can occur as a result of two different single-strand cleavage events. DNA cleavage can result in the production of blunt ends or staggered ends. In some embodiments, a complex comprising a guide RNA and a site-specific modifying enzyme is used for targeted double-stranded DNA cleavage.

[0054] By "cleavage domain" or "active domain" or "nuclease domain" of a nuclease is meant a polypeptide sequence or domain within a nuclease that has catalytic activity for DNA cleavage. A cleavage domain may be contained within a single polypeptide chain, or the cleavage activity may result from the association of two (or more) polypeptides. A single nuclease domain may consist of more than one isolated stretch of amino acids within a given polypeptide.

[0055] As used herein, the terms "treatment / treating" and the like generally mean obtaining a desired pharmacological and / or physiological effect. The effect is preventive in terms of completely or partially preventing a disease or its symptoms, and / or therapeutic in terms of partial or complete cure of a disease and / or adverse effects attributable to the disease. As used herein, "treatment" encompasses any treatment of a disease or symptom in a mammal, and includes: (a) preventing the disease or symptom from occurring in a subject who has a tendency to acquire the disease or symptom but has not yet been diagnosed with the disease or symptom; (b) inhibiting the disease or symptom, for example, curbing its development; or (c) alleviating the disease, for example, causing regression of the disease. Therapeutic agents may be administered before, during, or after the onset of a disease or injury. Of particular interest is the treatment of an ongoing disease, where the treatment stabilizes or reduces the patient's undesirable clinical symptoms. It is desirable to perform such treatment before complete loss of function in the affected tissue. It will be desirable to administer therapy during the symptomatic phase of the disease and in some cases after the symptomatic phase of the disease.

[0056] Headings such as (a), (b), (i), etc. are intended only to facilitate reading of the specification and claims. The use of headings in the specification or claims does not require that the steps or elements be performed in alphabetical or numerical order or in the order in which they are presented.

[0057] Lipid-based nanoparticle compositions of the present disclosure

[0058] In one aspect, a lipid-based nanoparticle (LNP) composition is provided herein, the lipid-based nanoparticle composition comprising: (a) a nucleic acid molecule containing a nucleotide sequence encoding a site-specific endonuclease; and (b) one or more lipid moieties, the one or more lipid moieties being selected from the group consisting of amino lipids, ionizable lipids, neutral lipids, PEG lipids, auxiliary lipids, and cholesterol or cholesterol derivatives; wherein the length of the nucleic acid molecule is about 3.8 kb or less (smLNP). In some embodiments, the nucleotide sequence encoding the site-specific endonuclease is operably linked to at least one additional nucleotide sequence. In some embodiments of the present disclosure, the site-specific endonuclease is a Cas9 protein or a functional derivative thereof. In some embodiments of the present disclosure, the nucleotide sequence encoding the site-specific endonuclease is codon-optimized to be expressed in a host cell. In some embodiments, the smLNP composition of the present disclosure further comprises one or more additional components of a CRISPR system. In some embodiments, the one or more additional components of the CRISPR system include a guide RNA (gRNA) or a nucleic acid molecule encoding the gRNA.

[0059] Nucleic acid molecules

[0060] The length of the nucleic acid molecule according to some embodiments of the smLNP compositions disclosed herein is about 3.8 kb, about 3.7 kb, about 3.6 kb, about 3.5 kb, about 3.4 kb, about 3.3 kb, about 3.2 kb, about 3.1 kb, or about 3.0 kb, including any range between these values. In some embodiments, the length of the nucleic acid molecule is about 2.9 kb, about 2.8 kb, about 2.7 kb, about 2.6 kb, about 2.5 kb, about 2.4 kb, about 2.3 kb, about 2.2 kb, about 2.1 kb, or about 2.0 kb, including any range between these values. In some embodiments, the length of the nucleic acid molecule is less than about 3.8 kb, less than about 3.7 kb, less than about 3.6 kb, less than about 3.5 kb, less than about 3.4 kb, less than about 3.3 kb, less than about 3.2 kb, less than about 3.1 kb, or less than about 3.0 kb. In some embodiments, the length of the nucleic acid molecule is less than about 2.9 kb, less than about 2.8 kb, less than about 2.7 kb, less than about 2.6 kb, less than about 2.5 kb, less than about 2.4 kb, less than about 2.3 kb, less than about 2.2 kb, less than about 2.1 kb, or less than about 2.0 kb. In some embodiments, the length of the nucleic acid molecule of the smLNP composition is between about 3.8 kb and about 2.0 kb, such as between about 3.7 kb and about 2.5 kb, between about 3.5 kb and about 2.6 kb, between about 3.2 kb and about 2.4 kb, or between about 3.0 kb and about 2.0 kb, such as between about 2.9 kb to 2.2 kb, between about 2.8 kb and about 2.3 kb, between about 2.7 kb and about 2.4 kb, between about 2.6 kb and about 2.5 kb, or between about 3.0 kb and about 2.5 kb. In some embodiments, the length of the nucleic acid molecule of the smLNP composition is about 3.5 kb.

[0061] In some embodiments, according to any of the smLNP compositions described herein, the nucleotide sequence encoding the site-specific endonuclease is operably linked to at least one additional nucleotide sequence. In some embodiments, at least one additional nucleotide sequence includes an untranslated terminal region (UTR), a common Kozak signal, a nucleotide sequence encoding a nuclear localization signal (NLS), a nucleotide sequence encoding a linker peptide, a nucleotide sequence encoding a tag peptide, or any combination thereof. In some embodiments, the common Kozak signal promotes the initial binding of mRNA to the ribosome, thereby enhancing its translation to a polypeptide product.

[0062] In some embodiments, according to any of the smLNP compositions described herein, the nucleic acid molecules of the smLNP compositions further comprise 3' and / or 5' untranslated regions (UTRs). In some embodiments, 3' or 5' UTRs are derived from human gene sequences. Non-limiting exemplary 3' and 5' UTRs include α- and β- globulins, albumin, HSD17B4, and eukaryotic elongation factor 1a. In addition, virally derived 5' and 3' UTRs may also be used and these UTRs include orthopoxvirus and cytomegalovirus UTR sequences. In some embodiments, 5' UTRs include the polynucleotide sequence of SEQ ID NO: 20. In some embodiments, 3' UTRs include the polynucleotide sequence of SEQ ID NO: 21. In some embodiments, mRNA includes a 5' cap, such as m7G (5') ppp (5') N. In addition, this cap is a cap-0 in which nucleotide N does not contain 2'OMe, or a cap-1 in which nucleotide N contains 2'OMe, or a cap-2 in which nucleotide N and N+1 contain 2'OMe. The cap may also have a structure such as m2 7'3"G(5')N incorporated by an anti-reverse cap analog (ARCA), and may also include similar structures such as cap-0, cap-1, and cap-2. In some embodiments, the 5' cap may regulate nuclear export; prevent degradation by exonucleases; promote translation; and promote 5' proximal intron excision. The stabilizing elements of the cap include phosphorothioate linkages, boranophosphate modifications, and methylene bridges. In addition, the cap may also contain a non-nucleic acid entity that functions as a binding element for eukaryotic translation initiation factor 4E (eIF4E). In some embodiments, the mRNA comprises a poly (A) tail. The length of this tail may be about 40 to about 300 nucleotides. In some embodiments, the length of the tail is about 40 to about 100. In some embodiments, the poly (A) tail is a polynucleotide having a length of about 100 to about 300 nucleotides. In some embodiments, the length of the tail is about 100 to about 200 nucleotides. In some embodiments, the length of the tail is about 50 to about 200 nucleotides. In some embodiments, the length of the tail is about 50 to about 250 nucleotides. In some embodiments, the length of the tail is about 100, 150 or 200 nucleotides. The poly (A) tail can contain modifications that prevent exonuclease degradation, including phosphorothioate linkages and modifications to the core base. In addition, the poly (A) tail can contain a 3' "cap", which can include modified or non-natural core bases or other synthetic moieties.

[0063] In some embodiments, according to any of the smLNP compositions described herein, the nucleic acid molecule of the smLNP composition comprises a nucleotide sequence encoding a nuclear localization signal (NLS). In some embodiments, the NLS comprises a nucleoplasmin NLS or a SV40 NLS. In some embodiments, the nucleoplasmin NLS comprises the amino acid sequence of SEQ ID NO: 23. In some embodiments, the nucleoplasmin NLS is encoded by the polynucleotide sequence of SEQ ID NO: 22. In some embodiments, the SV40 NLS comprises the amino acid sequence of SEQ ID NO: 25. In some embodiments, the SV40 NLS is encoded by the polynucleotide sequence of SEQ ID NO: 24. In some embodiments, the nucleic acid molecule comprises a nucleotide sequence encoding a nucleoplasmin NLS and a nucleotide sequence encoding a SV40 NLS.

[0064] As used herein, the term "site-directed endonuclease" refers to a nuclease used to cleave genomic DNA in genome editing.

[0065] In some embodiments, according to any of the smLNP compositions described herein, the nucleic acid molecules (e.g., RNA, such as mRNA) of the smLNP compositions comprise a nucleotide sequence encoding a site-specific endonuclease, which is a Cas protein (such as Cas9) or a functional derivative thereof. In some embodiments, the Cas protein is a "functional derivative" of a naturally occurring Cas protein. The term "functional derivative" of a native sequence polypeptide refers to a compound having a common qualitative biological property with a native sequence polypeptide. As used herein, "functional derivatives" include, but are not limited to, fragments of native sequences and derivatives of native sequence polypeptides and fragments thereof, provided that they have a common biological activity with the corresponding native sequence polypeptide. A non-limiting exemplary biological activity contemplated herein is the ability of a functional derivative to hydrolyze a DNA substrate into fragments. The term "derivative" encompasses amino acid sequence variants, covalent modifications, and fusions thereof of a polypeptide.

[0066] In some embodiments, according to any of the smLNP compositions described herein, the nucleic acid molecule component (e.g., RNA, such as mRNA) of the smLNP compositions disclosed herein comprises a nucleotide sequence encoding a site-specific endonuclease derived from one or more smCas9s. Gib11Spa1 endonuclease comprising an amino acid sequence of SEQ ID NO: 1 or a variant thereof having at least 90% sequence identity with SEQ ID NO: 1. In some embodiments, the site-specific endonuclease is a Gib11Spa3 endonuclease comprising an amino acid sequence of SEQ ID NO: 2 or a variant thereof having at least 90% sequence identity with SEQ ID NO: 2. In some embodiments, the site-specific endonuclease is an E2Cas9 endonuclease comprising an amino acid sequence of SEQ ID NO: 3 or a variant thereof having at least 90% sequence identity with SEQ ID NO: 3. In some embodiments, the site-specific endonuclease is a F8Cas9 endonuclease comprising an amino acid sequence of SEQ ID NO: 4 or a variant thereof having at least 90% sequence identity to SEQ ID NO: 4. In some embodiments, the site-specific endonuclease is a P2H12Cas9 endonuclease comprising an amino acid sequence of SEQ ID NO: 5 or a variant thereof having at least 90% sequence identity to SEQ ID NO: 5. In some embodiments, the site-specific endonuclease is a SluCas9 endonuclease comprising an amino acid sequence of SEQ ID NO: 6 or a variant thereof having at least 90% sequence identity to SEQ ID NO: 6.

[0067] In some embodiments, according to any of the smLNP compositions described herein, the nucleic acid molecule of the smLNP composition is an mRNA encoding a Cas nuclease, which is also referred to herein as a Cas nuclease mRNA. The mRNA can be modified to improve stability and / or immunogenic properties. One or more nucleosides within the mRNA can be modified. Examples of chemical modifications to mRNA nucleobases include pseudouridine, 1-methyl-pseudouridine (or N1-methylpseudouridine), 5-methoxyuridine, and 5-methyl-cytidine. In some embodiments, the mRNA contains an N1-methylpseudouridine base modification. In some embodiments, the mRNA contains a pseudouridine base modification. Additional known modifications that improve stability, expression, and immunogenicity are contemplated. The mRNA encoding the Cas nuclease can be codon-optimized for expression in a specific cell type, such as a eukaryotic cell, a mammalian cell, or more specifically a human cell. In some embodiments, the mRNA encodes a human codon-optimized Cas9 nuclease. In some embodiments, the mRNA is further modified by uridine depletion. In some embodiments, the mRNA is modified by uridine depletion and codon optimization (e.g., using Software platform) to modify the mRNA. In some embodiments, the mRNA is purified. In some embodiments, the mRNA is purified using a precipitation method. In some embodiments, the mRNA is purified using a chromatography-based method, such as an HPLC-based method or an equivalent method. In some embodiments, the mRNA is purified using both a precipitation method and an HPLC-based method.

[0068] In some embodiments, according to any of the smLNP compositions described herein, the site-specific endonuclease comprises an amino acid sequence having at least 95% identity to a site-specific endonuclease having an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO 5, and SEQ ID NO: 6. The term "percent identity" as used in the context of two or more nucleic acids or proteins refers to two or more sequences or subsequences that are identical or have a specified percentage of identical nucleotides or amino acids (e.g., about 60% sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more identity over a specified region when compared and aligned over a comparison window or specified region for maximum correspondence) as measured using the BLAST or BLAST 2.0 sequence comparison algorithm with the default parameters described below, or by manual alignment and visual inspection. See, e.g., the NCBI website at ncbi.nlm.nih.gov / BLAST. Such sequences are then said to be "substantially identical". This definition also refers to, or is applicable to, the complementary sequence of a test sequence. This definition also includes sequences with deletions and / or additions, as well as sequences with substitutions. Sequence identity typically exists over a region that is at least about 20 amino acids or nucleotides in length, or over a region that is 10-100 amino acids or nucleotides in length, or across the entire length of a given sequence.

[0069] If necessary, sequence identity can be calculated using published techniques and widely available computer programs such as the GCS program package (Devereux et al., Nucleic Acids Res. 12:387, 1984), BLASTP, BLASTN, FASTA (Atschul et al., J. Molecular Biol. 215:403, 1990). Sequence identity can be measured using sequence analysis software such as the Sequence Analysis Software Package of the Genetics Computer Group at the University of Wisconsin Biotechnology Center (1710 University Avenue, Madison, Wis. 53705) with its default parameters.

[0070] In some embodiments, according to any of the smLNP compositions described herein, the site-specific endonuclease comprises an amino acid sequence having at least 95%, at least 96%, at least 97%, at least 98, or at least 99% identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO 5, and SEQ ID NO: 6. In some embodiments, the site-specific endonuclease comprises an amino acid sequence having 100% identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO 5, and SEQ ID NO: 6.

[0071] In some embodiments, according to any of the smLNP compositions described herein, the nucleic acid molecule of the smLNP composition comprises a nucleotide sequence having at least 95% identity to a nucleotide sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12. In some embodiments, the nucleic acid molecule of the smLNP composition disclosed herein comprises a nucleotide sequence having at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to a nucleotide sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12. In some embodiments, the nucleic acid molecule of the smLNP composition disclosed herein comprises a nucleotide sequence having 100% identity to a nucleotide sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12.

[0072] In some embodiments, according to any of the smLNP compositions described herein, the nucleic acid molecule of the smLNP composition encodes a polypeptide comprising the amino acid sequence of any one of SEQ ID NOs: 35, 37, 39, 41, 43, 45, 47, and 49.

[0073] In some embodiments, according to any of the smLNP compositions described herein, the nucleic acid molecule of the smLNP composition comprises a polynucleotide sequence of any one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, and 48.

[0074] Sequence optimization of nucleotide sequences

[0075] In some embodiments, according to any of the smLNP compositions described herein, the nucleic acid molecules (e.g., RNA, such as mRNA) of the smLNP compositions comprise a sequence-optimized nucleotide sequence. In some embodiments, the nucleic acid molecules of the smLNP compositions disclosed herein comprise a nucleotide sequence encoding a site-specific endonuclease, which is sequence-optimized for expression in a target cell. The sequence-optimized nucleotide sequence encoding the site-specific endonuclease (e.g., a codon-optimized mRNA sequence) is typically a sequence comprising at least one synonymous nucleobase substitution relative to a reference sequence (e.g., a wild-type nucleotide sequence encoding a site-specific endonuclease). The sequence-optimized nucleotide sequence may be partially or completely different from the reference sequence in sequence. For example, a reference sequence encoding a polyserine uniformly encoded by a TCT codon can be sequence-optimized by replacing 100% of its nucleobases (for each codon, T in position 1 is replaced by A, C in position 2 is replaced by G, and T in position 3 is replaced by C) to generate a sequence encoding a polyserine uniformly encoded by an AGC codon. The percentage of sequence identity obtained from the global pairwise alignment between the reference polyserine nucleic acid sequence and the sequence-optimized polyserine nucleic acid sequence will be 0%. However, the protein products from the two sequences will be 100% identical. Some sequence optimization (sometimes also referred to as codon optimization) methods are known in the art and can be used to achieve one or more desired results. These results can include, for example, matching codon frequencies in certain tissue targets and / or host organisms to ensure correct folding; uridine depletion; biasing G / C content to increase mRNA stability or reduce secondary structure; minimizing tandem repeat sequence codons or base runs that may damage gene construction or expression; customizing transcription and translation control regions; inserting or removing protein transport sequences; removing / adding post-translational modification sites (e.g., glycosylation sites) in the encoded protein; adding, removing or reorganizing protein domains; inserting or deleting restriction sites; modifying ribosome binding sites and mRNA degradation sites; adjusting translation rates to allow each domain of the protein to fold correctly; and / or reducing or eliminating problematic secondary structures within polynucleotides.

[0076] Sequence optimization tools, algorithms, and services are known in the art. Non-limiting examples include those from GeneArt (Life Technologies), DNA2.0 (Menlo Park CA), And / or the service of proprietary methods. In some embodiments, the nucleic acid molecules (e.g., RNA, such as mRNA) of the smLNP compositions disclosed herein comprise a sequence-optimized nucleotide sequence (e.g., ORF) encoding a site-specific endonuclease or a functional derivative thereof, wherein the site-specific endonuclease or a functional derivative thereof encoded by the sequence-optimized nucleotide sequence has improved properties (e.g., compared to a site-specific endonuclease or a functional derivative thereof encoded by a reference nucleotide sequence that is not sequence-optimized), such as improved properties related to expression efficacy after in vivo administration. Such properties may include, but are not limited to, improving nucleic acid stability (e.g., mRNA stability), increasing translation efficacy in target tissues, reducing the number of truncated proteins expressed, improving folding of expressed proteins or preventing misfolding thereof, reducing the toxicity of expressed products, reducing cell death caused by expressed products, and increasing and / or reducing protein aggregation. In some embodiments, the sequence-optimized nucleotide sequence is codon-optimized for expression in human subjects, has structural and / or chemical features that avoid or reduce one or more problems known in the art, such as features that can be used to optimize the formulation and delivery of nucleic acid-based therapeutics while retaining structural and functional integrity; overcome thresholds for expression; improve expression rate, half-life, and / or protein concentration; optimize protein localization; and avoid deleterious biological responses, such as immune responses and / or degradation pathways. In some embodiments, the sequence-optimized nucleotide sequence is uridine-depleted. In some embodiments, the sequence-optimized nucleotide sequence is codon-optimized and uridine-depleted.

[0077] In some embodiments, according to any of the smLNP compositions described herein, the nucleic acid molecule (e.g., RNA, such as mRNA) of the smLNP composition comprises an optimized sequence selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19.

[0078] In some embodiments, according to any of the smLNP compositions described herein, the nucleic acid molecule (e.g., RNA, such as mRNA) of the smLNP composition comprises a nucleotide sequence codon-optimized for expression in a mammal. In some embodiments, the mammalian cell is a human cell, a murine cell, or a non-human primate (NHP) cell.

[0079] Additional components of the CRISPR / Cas system

[0080] In some embodiments, according to any of the smLNP compositions described herein, the smLNP composition further comprises one or more additional components of the CRISPR / Cas system. In principle, there is no particular limitation on the one or more additional components of the CRISPR / Cas system, so the one or more additional components can be selected from any known components of the CRISPR system. In some embodiments, the one or more additional components of the CRISPR system include guide RNA (gRNA). In some embodiments, the one or more additional components of the CRISPR system include nucleic acid molecules encoding gRNA.

[0081] The gRNA has at least a spacer sequence and a CRISPR repeat sequence (this CRISPR repeat sequence is also referred to as a "tracr partner sequence") that hybridizes with a target nucleic acid sequence of interest. In a type II system, the gRNA also has a second RNA called a tracrRNA sequence. In type II guide RNA (gRNA), the CRISPR repeat sequence and the tracrRNA sequence hybridize with each other to form a duplex. The duplex binds to a site-specific polypeptide so that the guide RNA and the site-specific endonuclease form a complex. In this case, the guide RNA and the site-specific endonuclease can form a ribonucleoprotein complex (e.g., bound via non-covalent interactions). The guide RNA of the complex provides target specificity for the complex by comprising a nucleotide sequence complementary to the target DNA sequence, and the site-specific endonuclease of the complex provides nuclease endonuclease activity. In other words, the site-specific endonuclease is guided to a target DNA sequence (e.g., a target sequence in a chromosomal nucleic acid; a target sequence in an extrachromosomal nucleic acid, such as an episomal nucleic acid, a minicircle, etc.; a target sequence in a mitochondrial nucleic acid; a target sequence in a chloroplast nucleic acid; a target sequence in a plasmid; etc.) by virtue of its association with the protein-binding segment of a guide RNA.

[0082] The guide RNA can be a single-molecule guide RNA, also referred to herein as a single guide RNA (sgRNA). In some embodiments, the guide RNA can include two RNA molecules and is referred to as "double guide RNA" or "dgRNA". In some embodiments, the dgRNA can include a first RNA molecule containing CRISPR RNA (crRNA) and a second RNA molecule containing tracr RNA. The first RNA molecule and the second RNA molecule can form an RNA duplex via base pairing between the flagpole on the crRNA and the tracr RNA. The double-molecule guide RNA has two RNA chains. The first chain has an optional spacer extension sequence, a spacer sequence, and a minimum CRISPR repeat sequence in the 5' to 3' direction. The second chain has a minimum tracrRNA sequence (complementary to the minimum CRISPR repeat sequence), a 3'tracrRNA sequence, and an optional tracrRNA extension sequence.

[0083] In some embodiments, according to any of the smLNP compositions described herein, the guide RNA comprises a single RNA molecule and is referred to as a "single guide RNA" or "sgRNA". In some embodiments, the sgRNA comprises a crRNA covalently linked to the tracr RNA. In some embodiments, the crRNA and tracr RNA are covalently linked via a linker. In some embodiments, the single molecule guide RNA comprises a stem-loop structure via base pairing between the crRNA and the flagpole on the tracr RNA.

[0084] The single molecule guide RNA (sgRNA) in the type II system has an optional spacer extension sequence, a spacer sequence, a minimum CRISPR repeat sequence, a single molecule guide joint, a minimum tracrRNA sequence, a 3'tracrRNA sequence, and an optional tracrRNA extension sequence in the 5' to 3' direction. The optional tracrRNA extension sequence may have an element that contributes additional functions (e.g., stability) to the guide RNA. The single molecule guide joint connects the minimum CRISPR repeat sequence and the minimum tracrRNA sequence to form a hairpin structure. The optional tracrRNA extension sequence has one or more hairpins.

[0085] In some embodiments, according to any of the smLNP compositions described herein, the nucleic acid molecule of the smLNP compositions disclosed herein is an mRNA encoding a Cas nuclease, which is also referred to herein as a Cas nuclease mRNA. The mRNA can be modified to improve stability and / or immunogenic properties. One or more nucleosides within the mRNA can be modified. Examples of chemical modifications of mRNA nucleobases include pseudouridine, 1-methyl-pseudouridine (or N1-methylpseudouridine), 5-methoxyuridine, and 5-methyl-cytidine. In some embodiments, the mRNA contains an N1-methylpseudouridine base modification. In some embodiments, the mRNA contains a pseudouridine base modification. Additional known modifications that improve stability, expression, and immunogenicity are contemplated. The mRNA encoding the Cas nuclease can be codon-optimized for expression in a specific cell type, such as a eukaryotic cell, a mammalian cell, or more specifically a human cell. In some embodiments, the mRNA encodes a human codon-optimized Cas9 nuclease. In some embodiments, the mRNA is further modified by uridine depletion. In some embodiments, the mRNA is modified by uridine depletion and codon optimization (e.g., using Software platform) to modify the mRNA. In some embodiments, the mRNA is purified. In some embodiments, the mRNA is purified using a precipitation method (e.g., LiCl precipitation, alcohol precipitation, or an equivalent method, e.g., as described herein). In some embodiments, the mRNA is purified using a chromatography-based method, such as an HPLC-based method or an equivalent method (e.g., as described herein). In some embodiments, the mRNA is purified using both a precipitation method (e.g., LiCl precipitation) and an HPLC-based method.

[0086] Amino lipids

[0087] In some embodiments, the smLNP compositions disclosed herein may include one or more amino lipids. The terms "amino lipid" and "cationic lipid" are used interchangeably herein to include those lipids and salts thereof having one, two, three, or more fatty acids or fatty alkyl chains and pH titratable amino head groups (e.g., alkylamino or dialkylamino head groups). In principle, there are no particular restrictions on the amino lipids of the smLNP compositions disclosed herein. Cationic lipids are typically protonated (i.e., positively charged) at a pH lower than the pKa of the cationic lipid, and are substantially neutral at a pH higher than the pKa. The cationic lipids disclosed herein may also be referred to as titratable cationic lipids. In some embodiments, the one or more cationic lipids include: a protonable tertiary amine (e.g., pH titratable) head group; an alkyl chain, wherein each alkyl chain independently has 0 to 3 (e.g., 0, 1, 2, or 3) double bonds; and an ether, ester, or ketal linkage between the head group and the alkyl chain. Such cationic lipids include, but are not limited to, DSDMA, DODMA, DOTMA, DLinDMA, DLenDMA, γ-DLenDMA, DLin-K-DMA, DLin-K-C2-DMA (also known as DLin-C2K-DMA, XTC2, and C2K), DLin-K-C3-DMA, DLin-K-C4-DMA, DLen-C2K-DMA, y-DLen-C2-DMA, C12-200, cKK-E12, cKK-A12, cKK-O12, DLin-MC2-DMA (also known as MC2), and DLin-MC3-DMA (also known as MC3).

[0088] Helper lipids

[0089] In certain embodiments, the smLNP compositions disclosed herein include one or more auxiliary lipids. As used herein, the term "auxiliary lipid" refers to a lipid that enhances transfection (e.g., transfection of nanoparticles of nucleic acid molecules containing nucleotide sequences encoding site-specific endonucleases). In principle, there are no particular restrictions on the auxiliary lipids of the smLNP compositions disclosed herein. Without being bound by any particular theory, it is believed that the mechanism by which auxiliary lipids enhance transfection includes enhancing particle stability. In certain embodiments, auxiliary lipids enhance membrane fusogenicity. Typically, the auxiliary lipids of the smLNP compositions disclosed herein can be any auxiliary lipids known in the art. Non-limiting examples of auxiliary lipids suitable for the compositions and methods disclosed herein include steroids, sterols, and alkylresorcinols. Particularly useful auxiliary lipids for the present disclosure include, but are not limited to, saturated phosphatidylcholines (PC) such as distearoyl-PC (DSPC) and dipalmitoyl-PC (DPPC), dioleoylphosphatidylethanolamine (DOPE), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), cholesterol, 5-heptadecanol resorcinol, and cholesterol hemisuccinate. In some embodiments, the auxiliary lipid of the smLNP composition includes cholesterol.

[0090] Structural lipids

[0091] In certain embodiments, the smLNP compositions disclosed herein may include one or more structural lipids. As used herein, the term "structural lipid" refers to sterols and also refers to lipids containing sterol moieties. Without being bound by any particular theory, it is believed that the incorporation of structural lipids in the smLNPs disclosed herein can help to alleviate the aggregation of other lipids in the particles. The structural lipids may be selected from the group consisting of, but not limited to, cholesterol, coprostanol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatine, tomatin, ursolic acid, alpha-tocopherol, hornane, phytosterol, steroids, and mixtures thereof. In certain embodiments, the structural lipid is cholesterol.

[0092] In some embodiments, the amount of structural lipids (e.g., sterols such as cholesterol) in the smLNP compositions disclosed herein is from about 10mol% to about 80mol%, from about 20mol% to about 70mol%, from about 30mol% to about 60mol%, or from about 40mol% to about 50mol%. In some embodiments, the amount of structural lipids in the smLNP compositions disclosed herein is from about 25mol% to about 30mol%, from about 30mol% to about 35mol%, or from about 35mol% to about 40mol%. In some embodiments, the amount of structural lipids (e.g., sterols such as cholesterol) in the lipid compositions disclosed herein is about 24mol%, about 29mol%, about 34mol%, or about 39mol%. In some embodiments, the amount of structural lipids in the smLNP compositions disclosed herein is at least about 10 mol%, 20 mol%, 25 mol%, 30 mol%, 35 mol%, 40 mol%, 45 mol%, 50 mol%, 55 mol%, 60 mol%, 65 mol%, 70 mol%, 75 mol%, or 80 mol%.

[0093] Phospholipids

[0094] In some embodiments, the smLNP compositions disclosed herein comprise one or more phospholipids. In some embodiments, the phospholipids are selected from the group consisting of 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DS ...DSPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl PC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 diether PC), 1-oleoyl-2-cholesteryl hemisuccinyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME16:0PE), 1,2-distearoyl-sn-glycero-3 -phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-diamidoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, sodium salt of 1,2-dioleoyl-sn-glycero-3-phospho-racem-(1-glycerol) (DOPG), sphingomyelin, and any mixture thereof.

[0095] Ionizable lipids

[0096] In some embodiments, the smLNP compositions disclosed herein include one or more ionizable lipids. In principle, there is no particular limitation on the ionizable lipids of the smLNP compositions disclosed herein. In some embodiments, the one or more ionizable lipids are selected from the group consisting of: 3-(didodecylamino)-N1,N1,4-tridodecyl-1-piperazineethylamine (KL10), N1-[2-(didodecylamino)ethyl]-N1,N4,N4-tridodecyl-1,4-piperazinediethylamine (KL22), 14,25-ditridecyl-15,18,21,24-tetraaza-trioctadecane (KL25), 1,2-dilinoleyloxy-N,N-dimethylaminopropane (D Lin-DMA), 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), heptathriacontane-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butyrate (DLin-MC3-DMA), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA), 1,2-dioleyloxy-N,N-dimethylaminopropane (DODMA), 2-({8-[ -cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadec-9,12-dien-1-yloxy]propan-1-amine (octyl-CLinDMA), (2R)-2-({8-[ -cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadec-9,12-dien-1-yloxy]propan-1-amine (octyl-CLinDMA(2R)), and (2S)-2-({8-[ -cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadec-9,12-dien-1-yloxy]propan-1-amine (octyl-CLinDMA(2S)).

[0097] PEG-lipid

[0098] In some embodiments, the smLNP compositions disclosed herein include one or more polyethylene glycol (PEG) lipids. The term "PEG-lipid" refers to a lipid modified by polyethylene glycol (PEG). Such lipids are also referred to as PEGylated lipids. Non-limiting examples of PEG-lipids include PEG-modified phosphatidylethanolamine and phosphatidic acid, PEG-ceramide conjugates (e.g., PEG-CerC14 or PEG-CerC20), PEG-modified dialkylamines, and PEG-modified 1,2-diacyloxypropane-3-amines. For example, the PEG lipid can be PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, or PEG-DSPE lipids. In some embodiments, PEG-lipids include but are not limited to 1,2-dimyristoyl-sn-glyceromethoxypolyethylene glycol (PEG-DMG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino (polyethylene glycol)] (PEG-DSPE), PEG-disteryl glycerol (PEG-DSG), PEG-dipalmitoyl, PEG-dioleyl, PEG-distearoyl, PEG-diacylglycamide (PEG-DAG), PEG-dipalmitoyl phosphatidylethanolamine (PEG-DPPE), or PEG-l,2-dimyristyloxypropyl-3-amine (PEG-c-DMA). In one embodiment, PEG-lipids are selected from the group consisting of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol, and mixtures thereof. In some embodiments, the lipid portion of the PEG-lipid includes a PEG-lipid having from about C 14 to about C 22 , preferably from about C 14 to about C 16 In some embodiments, the PEG portion (e.g., mPEG-NH2) has a size of about 1000, 2000, 5000, 10,000, 15,000, or 20,000 Daltons. In some embodiments, the PEG-lipid is PEG2k-DMG. In some embodiments, the one or more PEG lipids of the smLNP composition include PEG-DMPE. In some embodiments, the one or more PEG lipids of the smLNP composition include PEG-DMG.

[0099] In some embodiments, the amount of PEG-lipid in the smLNP compositions disclosed herein is from about 0.1 mol% to about 5 mol%, from about 0.5 mol% to about 5 mol%, from about 1 mol% to about 5 mol%, from about 1.5 mol% to about 5 mol%, from about 2 mol% to about 5 mol%mol%, from about 0.1 mol% to about 4 mol%, from about 0.5 mol% to about 4 mol%, from about 1 mol% to about 4 mol%, from about 1.5 mol% to about 4 mol%, from about 2 mol% to about 4 mol%, from about 0.1 In some embodiments, the amount of PEG-lipid in the lipid composition disclosed herein is about 2mol%. In some embodiments, the amount of PEG-lipid in the lipid composition disclosed herein is about 1.5mol%.

[0100] In some embodiments, the amount of PEG-lipid in the smLNP compositions disclosed herein is at least about 0.1 mol%, 0.2 mol%, 0.3 mol%, 0.4 mol%, 0.5 mol%, 0.6 mol%, 0.7 mol%, 0.8 mol%, 0.9 mol%, 1.0 mol%, 1.1 mol%, 1.2 mol%, 1.3 mol%, 1.4 mol%, 1.5 mol%, 1.6 mol%, 1.7 mol%, 1.8 mol%, 1.9 mol%, 2.0 mol%, 2.1 mol%, 2.2 mol%, 2.3 mol%, 2.4 mol%, 2.5 mol%, 2.6 mol%, 2.7 mol%, 2.8 mol%, %. PEG-lipids are known in the art, and additional information thereof can be found in, for example, U.S. Pat. No. 8,158,601 and International Publication No. WO 2015 / 130584 A2.

[0101] In some specific embodiments, the smLNP compositions described herein comprise the following lipids: C12-200 amino lipids; 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE); cholesterol; and PEG-DMPE. In some embodiments, the LNP compositions described herein comprise the following lipids: DLin-M-C3-DMA (also known as MC3), 1,2-dimyristoyl-sn-glyceromethoxypolyethylene glycol (PEG-DMG), and / or 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).

[0102] The ratio between the lipid component of the smLNP compositions disclosed herein and the nucleic acid molecule encoding the site-specific endonuclease can be in the range of from about 10:1 to about 100:1 (wt / wt), such as, for example, from 10:1 to about 90:1, from 20:1 to about 80:1, from 30:1 to about 70:1, from 40:1 to about 60:1, or from 10:1 to about 50:1, such as, for example, from 10:1 to about 45:1, from 15:1 to about 40:1, from 20:1 to about 35:1, from 25:1 to about 30:1, or from 10:1 to about 40:1, from 15:1 to about 50:1, from 20:1 to about 30:1, or from 10:1 to about 30:1. In some embodiments, the ratio between the lipid component and the nucleic acid molecule encoding the site-specific endonuclease is about 10: 1, 15: 1, 20: 1, 25: 1, 30: 1, 35: 1, 40: 1, 45: 1, 50: 1, 55: 1, 60: 1, 65: 1, 70: 1, 75: 1, 80: 1, 85: 1, 90: 1, 95: 1, 100: 1. In some embodiments, the wt / wt ratio of the lipid component to the nucleic acid molecule encoding the site-specific endonuclease is about 20: 1 or about 15: 1.

[0103] In some embodiments, the smLNP compositions disclosed herein can contain more than one nucleic acid molecule each encoding a site-specific endonuclease. For example, the pharmaceutical compositions disclosed herein can contain two or more nucleic acid molecules (e.g., RNA, such as mRNA) each encoding a site-specific endonuclease. In some embodiments, the smLNP compositions described herein can comprise nucleic acid molecules (e.g., mRNA) in a lipid:polynucleotide weight ratio of 5:1, 10:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, 55:1, 60:1, or 70:1, or a range of these ratios or any of these ratios, such as, but not limited to, 5:1 to about 10:1, from about 5:1 to about 15:1, from about 5:1 to about 20:1, from about 5:1 to about 25:1, from about 5:1 to about 30:1, from about 5:1 to about 35:1, from about 5:1 to about 40:1, from about 5:1 to about 45:1, from about 5:1 to about 50:1, from about 5:1 to about 55:1, from about 5:1 to about 60:1, from about 5:1 to about 1, from about 10:1 to about 15:1, from about 10:1 to about 20:1, from about 10:1 to about 25:1, from about 10:1 to about 30:1, from about 10:1 to about 35:1, from about 10:1 to about 40:1, from about 10:1 to about 45:1, from about 10:1 to about 50:1, from about 10:1 to about 55:1, from about 10:1 to about 60:1, from about 10:1 to about 70:1, from about 10:1 to about 15:1, from about 10:1 to about 20:1, from about 10:1 to about 25:1, from about 10:1 to about 30:1, from about 10:1 to about 35:1, from about 10:1 to about 40:1, from about 10:1 to about 45:1, from about 10:1 to about 50:1, from about 10:1 to about 55:1, from about 10:1 to about 60:1, from about 10 :1 to about 70:1, from about 15:1 to about 20:1, from about 15:1 to about 25:1, from about 15:1 to about 30:1, from about 15:1 to about 35:1, from about 15:1 to about 40:1, from about 15:1 to about 45:1, from about 15:1 to about 50:1, from about 15:1 to about 55:1, from about 15:1 to about 60:1 or from about 15:1 to about 70:1.

[0104] In some embodiments, the lipid nanoparticles described herein comprise the nucleic acid molecules at a concentration from about 0.1 mg / mL to 2 mg / mL, such as, but not limited to, 0.1 mg / mL, 0.2 mg / mL, 0.3 mg / mL, 0.4 mg / mL, 0.5 mg / mL, 0.6 mg / mL, 0.7 mg / mL, 0.8 mg / mL, 0.9 mg / mL, 1.0 mg / mL, 1.1 mg / mL, 1.2 mg / mL, 1.3 mg / mL, 1.4 mg / mL, 1.5 mg / mL, 1.6 mg / mL, 1.7 mg / mL, 1.8 mg / mL, 1.9 mg / mL, 2.0 mg / mL or greater than 2.0 mg / mL.

[0105] Preparation of LNPs

[0106] The lipid nanoparticles of the present disclosure (wherein nucleic acid molecules (e.g., mRNA) are embedded in the lipid portion of the particle and protected from degradation) can be formed by any method known in the art, including but not limited to continuous mixing methods, direct dilution methods, and online dilution methods. Other techniques and methods suitable for preparing lipid nanoparticles described herein include coacervation, microemulsions, supercritical fluid technology, phase transition temperature (PIT) technology.

[0107] In certain embodiments, the smLNP of the present disclosure is produced via a continuous mixing method, which is, for example, a process comprising the following steps: providing an aqueous solution comprising a nucleic acid molecule (e.g., mRNA) in a first reservoir, providing an organic lipid solution (wherein the lipid present in the organic lipid solution is dissolved in an organic solvent, for example, a lower alkanol such as ethanol) in a second reservoir, and mixing the aqueous solution with the organic lipid solution so that the organic lipid solution is mixed with the aqueous solution to substantially instantaneously produce a lipid vesicle (e.g., liposome), thereby encapsulating the nucleic acid molecule in the lipid vesicle. This process and equipment for carrying out this method are known in the art. More information in this regard can be found in, for example, U.S. Patent Publication No. 20040142025, the disclosure of which is incorporated herein by reference. The action of lipid and buffer solution being continuously introduced into a mixed environment (such as being introduced into a mixing chamber) causes continuous dilution of the lipid solution with a buffer solution, thereby substantially instantaneously producing a lipid vesicle when mixing. Nucleic acid-lipid particles are produced by mixing an aqueous solution comprising nucleic acid molecules with an organic lipid solution that undergoes serial stepwise dilution in the presence of a buffer solution (eg, an aqueous solution).

[0108] In some embodiments, the smLNPs disclosed herein are produced via a direct dilution method comprising forming a lipid vesicle (e.g., liposome) solution and immediately directly introducing the lipid vesicle solution into a collection vessel containing a controlled amount of dilution buffer. In some embodiments, the collection vessel comprises one or more elements configured to stir the contents of the collection vessel to facilitate dilution. In some embodiments, the amount of dilution buffer present in the collection vessel is substantially equal to the volume of the lipid vesicle solution introduced therein.

[0109] In certain embodiments, the smLNP of the present disclosure is produced via an online dilution method, wherein the third reservoir fluid containing dilution buffer is connected to the second mixing zone. In these embodiments, the lipid vesicle (e.g., liposome) solution formed in the first mixing zone is immediately directly mixed with the dilution buffer in the second mixing zone. These processes and equipment for performing direct dilution and online dilution methods are known in the art. More information in this regard can be found in, for example, U.S. Patent Publication No. 20070042031, the disclosure of which is incorporated herein by reference.

[0110] Physicochemical properties of the smLNPs disclosed herein

[0111] In some embodiments, the smLNPs of the smLNP compositions disclosed herein have a lower rate of change of physicochemical properties than the LNPs of a reference LNP composition, the reference LNP composition comprising a nucleic acid molecule containing a nucleotide sequence encoding a site-specific endonuclease, wherein the nucleic acid molecule is greater than about 4 kb. In some embodiments, the rate of change of physicochemical properties of the smLNPs of the smLNP compositions disclosed herein is at least about 5% less than the corresponding rate of the LNPs of the reference LNP composition. In some embodiments, the rate of change of physicochemical properties of the smLNPs of the smLNP compositions disclosed herein is at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100% less than the corresponding rate of the LNPs of the reference LNP composition. In some embodiments, the change in physicochemical properties is the degradation rate of the smLNPs of the smLNP composition, as determined by the concentration and / or size of the smLNPs in the smLNP composition over time. In some embodiments, the degradation rate of the smLNPs of the smLNP compositions as disclosed herein is at least about 5% less than the corresponding rate of the LNPs of the reference LNP compositions. In some embodiments, the degradation rate of the smLNPs of the smLNP compositions as disclosed herein is at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100% less than the corresponding rate of the LNPs of the reference LNP compositions.

[0112] Functional properties of the LNPs disclosed herein

[0113] In some embodiments, the smLNPs of the smLNP compositions disclosed herein have a lower rate of functional performance reduction compared to the rate of functional performance reduction of a reference LNP composition, the reference LNP composition comprising a nucleic acid molecule containing a nucleotide sequence encoding a site-specific endonuclease, wherein the nucleic acid molecule is greater than about 4 kb. In some embodiments, the rate of functional performance reduction of the smLNPs of the smLNP compositions disclosed herein is at least about 5% less than the corresponding rate of the LNPs of the reference LNP composition. In some embodiments, the rate of functional performance reduction of the smLNPs of the smLNP compositions disclosed herein is at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100% less than the corresponding rate of the LNPs of the reference LNP composition.

[0114] In some embodiments, the functional performance reduction rate is determined by the genome editing efficiency of the smLNP containing the site-specific nuclease. In some embodiments, the editing efficiency of the smLNP of the smLNP composition disclosed herein is at least about 5% less than the corresponding efficiency of the LNP of the reference LNP composition. In some embodiments, the editing efficiency of the smLNP of the smLNP composition disclosed herein is at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100% less than the corresponding efficiency of the LNP of the reference LNP composition.

[0115] In some embodiments, the smLNPs of the smLNP compositions disclosed herein have an average particle diameter that is greater than the average particle diameter of the LNPs of a reference LNP composition comprising a nucleic acid molecule comprising a nucleotide sequence encoding a site-specific endonuclease, wherein the nucleic acid molecule is greater than about 4.0 kb. In some embodiments, the average particle diameter of the smLNPs of the smLNP compositions disclosed herein is at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% greater than the average particle diameter of the LNPs in the reference LNP composition.

[0116] Pharmaceutical composition

[0117] In one aspect, the smLNPs as described herein are incorporated into a composition, such as a pharmaceutical composition. Such compositions typically comprise smLNPs and a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically acceptable carrier" includes, but is not limited to, saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc. that are compatible with drug administration. Supplementary active compounds (e.g., anticancer agents) may also be incorporated into the composition. Therefore, some embodiments of the present disclosure relate to a pharmaceutical composition comprising a smLNP composition as described herein and a pharmaceutically acceptable carrier.

[0118] Some embodiments of the present disclosure relate to a pharmaceutical composition comprising a smLNP composition as described herein, for use in delivering a biomolecule (such as a site-specific endonuclease or a nucleic acid molecule encoding the site-specific endonuclease) to a target cell. In a related aspect, some embodiments of the present disclosure relate to a pharmaceutical composition comprising a smLNP composition as described herein, for use in editing the genome of a cell. In another related aspect, some embodiments of the present disclosure provide a smLNP or composition (e.g., a pharmaceutical composition) for use in treating a health condition or disease of a mammal (e.g., a human).

[0119] Methods of the Disclosure

[0120] Once formed, the smLNPs disclosed herein are particularly useful for introducing nucleic acid molecules comprising, for example, a nucleotide sequence encoding a site-specific endonuclease into one or more cells in a subject or organism. Accordingly, some embodiments of the disclosure relate to a method for delivering nucleic acid molecules into a cell, the method comprising contacting the cell with a smLNP composition or pharmaceutical composition as disclosed herein, wherein the LNP composition comprises a nucleic acid molecule. The method can be performed in vitro or in vivo by first forming a smLNP as described above, and then contacting the smLNP with the cell for a period of time sufficient to allow delivery of the nucleic acid molecule to the cell to occur.

[0121] In some embodiments, the method includes administering the smLNP or pharmaceutical composition disclosed herein under conditions suitable for delivering the bioactive molecule component (e.g., nucleic acid molecule) to one or more cells of a subject or organism. In some embodiments, the smLNP or pharmaceutical composition is contacted with one or more cells of a subject or organism as generally known in the art, such as via parenteral administration (e.g., intravenous, intramuscular, subcutaneous administration) of a molecular composition formulated with or without an excipient that facilitates administration.

[0122] In another aspect, some embodiments of the present disclosure relate to a method for editing the genome of a cell, the method comprising providing a smLNP composition or a pharmaceutical composition as disclosed herein to the cell. In some embodiments, the smLNP or composition disclosed herein improves the gene editing efficiency in a host cell or organism. In some embodiments, the gene editing efficiency conferred by the LNP composition of the present disclosure is greater than the gene editing efficiency of a reference LNP composition, the reference LNP composition comprising a nucleic acid molecule containing a nucleotide sequence encoding a site-specific endonuclease, wherein the nucleic acid molecule is greater than about 4kb. In some embodiments, the editing efficiency of the smLNP composition is at least about 5% greater than the editing efficiency of the reference LNP composition. In some embodiments, the editing efficiency of the smLNP composition is at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100% greater than the editing efficiency of the reference LNP composition. In some embodiments, the editing efficiency of the smLNP composition is at least two times, at least three times, at least four times, at least five times, at least six times, or at least seven times greater than the editing efficiency of the reference LNP composition. In some embodiments, the editing efficiency of the smLNP composition is at least eight times, at least nine times, or at least ten times greater than the editing efficiency of the reference LNP composition.

[0123] The method disclosed herein can be practiced in a variety of host cells and organisms. Suitable hosts include animal species, including mammalian species, such as primates (e.g., humans and chimpanzees and other non-human primates), canines, felines, equines, bovines, bovines, rodents (e.g., rats and mice), lagomorphs, and pigs. In some embodiments of the method disclosed herein, the host cell is a mammalian cell. In certain embodiments, the mammalian cell is a human cell, a murine cell, or a non-human primate cell.

[0124] Treatment

[0125] In one aspect, some embodiments of the present disclosure relate to a method for treating one or more symptoms associated with a health condition or disease in a mammal (e.g., a human) in need thereof, preventing the one or more symptoms, reducing the risk or likelihood of developing (e.g., reducing susceptibility to), delaying the onset of the one or more symptoms, and / or ameliorating the one or more symptoms, the method comprising administering to the mammal a therapeutically effective amount of a smLNP composition comprising a nucleic acid molecule encoding a site-specific nuclease targeting a gene of interest as described herein.

[0126] As used herein, the term "administration" or "administering" refers to delivery of a biologically active composition or formulation by a route of administration including, but not limited to, oral, intravenous, intraarterial, intramuscular, intraperitoneal, subcutaneous, intramuscular, and topical administration, or a combination thereof. The term includes, but is not limited to, administration by a medical professional or self-administration.

[0127] In some embodiments, the health condition or disease is hemophilia A. In some embodiments, the health condition or disease is cardiovascular disease.

[0128] Hemophilia A

[0129] Some embodiments of the present disclosure relate to methods for treating, preventing, reducing the risk or likelihood of developing, delaying the onset of, and / or ameliorating one or more symptoms associated with a health condition or disease in a mammal (e.g., a human) in need thereof, wherein the health condition or disease is hemophilia A.

[0130] Hemophilia A (HemA) is caused by a genetic defect in the factor VIII (FVIII) gene that results in low or undetectable levels of FVIII protein in the blood. This results in ineffective clot formation at sites of tissue damage, often leading to joint damage and hemophilic arthropathy over time. Other potentially serious bleeding problems include intracranial bleeding and potentially uncontrollable bleeding, which can be fatal if not treated.

[0131] The FVIII gene is primarily expressed in the hepatic sinusoidal endothelial cells present in the liver and other sites in the body. Exogenous FVIII can be expressed and secreted from the hepatocytes of the liver, thereby producing FVIII in the circulation and thus achieving cure of the disease.

[0132] Rationale for addressing hemophilia A disease through genome editing

[0133] Although a variety of gene therapy methods are currently under development or in clinical practice, they have undesirable characteristics. Virus-based gene therapy using adeno-associated virus (AAV) has shown promise in preclinical animal models and patients, but it has multiple disadvantages. Gene therapy based on AAV uses a FVIII gene encapsulated in an AAV viral capsid (typically using serotypes AAV5, AAV8, AAV9 or AAVrh10, etc.) driven by a liver-specific promoter. All AAV viruses used for gene therapy deliver the packaged gene cassette to the nucleus of the transduced cell, where the gene cassette is almost only kept as an episomal and it is a free copy of the therapeutic gene producing therapeutic protein. AAV does not have a mechanism for integrating its encapsulated DNA into the genome of the host cell, but is kept as an episome, which is therefore not replicated when the host cell divides. Free DNA may also be subject to degradation over time. It has been shown that when liver cells containing AAV episomes are induced to divide, the AAV genome is not replicated but diluted. Therefore, it is expected that AAV-based gene therapy will not be effective when given to children whose livers have not yet reached adult size. In addition, it is not yet known how long AAV-based gene therapy will last when given to adults, but animal data have demonstrated only a small loss of therapeutic effect over a period of up to 10 years. A permanent cure for HemA is highly desirable, especially if FVIII levels within the normal range can be achieved. However, currently available HemA treatments have multiple limitations. For example, replacing the missing FM protein is an effective treatment for HemA patients and is the current standard of care. However, protein replacement therapy requires frequent intravenous injections of FVIII protein, which is inconvenient for adults, problematic for children, costly, and may lead to breakthrough bleeding events if the treatment regimen is not strictly followed. In another example, the novel bispecific antibody Hemlibra has recently been approved and represents the first antibody-based therapeutic agent for the treatment of HemA. This molecule acts as a FVIIIa mimetic and can be delivered subcutaneously with a potential treatment duration of 1 month. During clinical trials, when the FVIIIa mimetic is administered to children, the FVIIIa mimetic is administered to children with FVIIIa. There has been a death when FEIBA was used in combination with the bypass agent to treat breakthrough bleeding. In addition, there has been a recent report of anti-drug antibodies in one patient.

[0134] Therefore, there is an urgent need to develop new effective and durable treatments for HemA that can be achieved through genome editing. The applicant envisions conducting experiments to target genome editing at the human albumin locus. Human albumin intron 1-albumin (located on chromosome 4q13.3) is an abundant liver protein expressed by hepatocytes and is the most highly expressed protein found in plasma. Without being bound by any particular theory, it is believed that targeted integration into 1% of the albumin gene will not affect albumin expression levels while providing sufficient FVIII expression to normalize activity.

[0135] In some embodiments, the smLNP compositions according to some embodiments of the present disclosure are deployed for inserting the FVIII gene into liver hepatocytes. In these cases, the smLNP compositions are preferentially taken up by liver cells (e.g., hepatocytes). In some embodiments, the smLNP compositions used in the method for treating hemophilia A are biodegradable because they do not accumulate to cytotoxic levels in vivo at therapeutically effective doses. In some embodiments, the smLNP compositions used in the method for treating hemophilia A do not cause an innate immune response that causes significant adverse effects at therapeutic dose levels. In some embodiments, the smLNP compositions do not cause toxicity at therapeutic dose levels. In some embodiments, the smLNP compositions disclosed herein specifically bind to apolipoproteins (such as apolipoprotein E (ApoE)) in the blood. Apolipoproteins are proteins that circulate in plasma, and these proteins are key to regulating lipid transport. ApoE represents a class of apolipoproteins that interact with cell surface heparin sulfate proteoglycans in the liver during lipoprotein uptake.

[0136] Cardiovascular disease

[0137] Some embodiments of the present disclosure relate to methods for treating, preventing, reducing the risk or likelihood of developing, delaying the onset of, and / or ameliorating one or more symptoms associated with a health condition or disease in a mammal (e.g., a human) in need thereof, wherein the health condition or disease is cardiovascular disease.

[0138] High levels of lipoprotein particles Lp (a) are associated with cardiovascular disease, or the risk of developing cardiovascular disease. For example, high plasma levels of Lp (a) are independent risk factors for calcific aortic valve disease, coronary heart disease, atherosclerosis, thrombosis, and stroke. Interestingly, the range of plasma Lp (a) levels in humans varies 1000 times between individuals. This wide range suggests that significantly reducing plasma Lp (a) may not be harmful and therefore potential anti-Lp (a) drugs may have a wide therapeutic window.

[0139] Due to the lack of treatments that reliably and stably reduce Lp(a) levels, therapies that permanently reduce Lp(a) levels are highly desirable. Since hepatocytes are the major source of apo(a), gene editing approaches directed to "targeted knockout" of apo(a) in the liver would be an attractive approach.

[0140] Unlike LDL, Lp(a) levels cannot be regulated by the environment, diet, or existing lipid-lowering drugs (such as statins), making it a strictly genetically driven disease risk factor. Antisense oligonucleotides targeting apo(B) can reduce Lp(a) by 25% (Santos et al., Arterioscler Thromb Vasc Biol. [Arteriosclerosis, thrombosis and vascular biology] March 2015; 35(3): 689-699). Subsequently, antisense therapies specifically targeting apo(a) mRNA were tested in clinical trials and showed a significant reduction of plasma Lp(a) levels by more than 80% (Viney et al., Lancet [Lancet] 2016; 388: 2239-53). Unfortunately, antisense therapies require frequent dosing to be effective.

[0141] Therefore, there is an urgent need to develop new effective and lasting treatments for cardiovascular disease that can be achieved through genome editing. In some embodiments of the present disclosure, the applicant envisions conducting experiments to target genome editing at the human lipoprotein (a) (LPA) locus located on chromosome 6q25.3-q26. Lipoprotein (a) is an atherogenic lipoprotein that consists of a protein apolipoprotein (a) [apo (a)] covalently bound to the apolipoprotein B-100 (apoB) component of low-density lipoprotein (LDL) particles. The apo (a) protein is encoded by the LPA gene, produced in hepatocytes and secreted into the circulation. The pathogenic mechanism of Lp (a) is mediated by its pro-atherogenic, pro-inflammatory, and pro-thrombotic properties. The combination of apo (a) and the LDL component of Lp (a) produces a compound effect on the cardiovascular system. LDL alone can cause immune and inflammatory responses that characterize atherosclerosis in the following ways: LDL enters the vascular wall, where phospholipids are oxidized. Lp(a) circulates and binds to oxidized phospholipids in plasma, causing a pro-inflammatory response. Apo(a) itself contains sites that can bind to exposed surfaces on damaged blood vessel walls, mediating its entry and accumulation at these locations. Small isoforms of apo(a) have been shown to promote thrombosis by inhibiting fibrinolysis. In some embodiments, the LNP compositions according to some embodiments of the present disclosure are designed to delete the LPA gene in liver hepatocytes.

[0142] Implementations of embodiments of the methods of the present disclosure may include one or more of the following features.

[0143] As used herein, "administration / administering" refers to delivering a bioactive composition or formulation by a route of administration including, but not limited to, oral, intravenous, intraarterial, intramuscular, intraperitoneal, subcutaneous, intramuscular, and topical administration, or a combination thereof. The term includes, but is not limited to, administration by a medical professional or self-administration. Therefore, in some embodiments of the methods disclosed herein, the LNP or composition described herein (e.g., pharmaceutical composition) is administered by one of the following routes of administration: oral, intranasal, intravenous, intraperitoneal, intramuscular, intraarticular, intralesional, intratracheal, subcutaneous, and intradermal. In some embodiments, the LNP or composition disclosed herein is administered systemically, for example, via an enteral or parenteral route of administration.

[0144] Typically, the smLNP or composition disclosed herein is formulated to be compatible with its intended route of administration. The smLNP and composition disclosed herein are administered orally or by inhalation, but they are more likely to be administered by a parenteral route. Examples of parenteral routes of administration include, for example, intravenous, intradermal, subcutaneous, transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions for parenteral applications may include the following components: a sterile diluent, such as water for injection, saline solution, non-volatile oil, polyethylene glycol, glycerol, propylene glycol or other synthetic solvents; antibacterial agents, such as benzyl alcohol or methyl paraben; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid (EDTA); buffers, such as acetates, citrates or phosphates; and agents for adjusting tension, such as sodium chloride or dextrose. The pH can be adjusted (e.g., to a pH of about 7.2-7.8, e.g., 7.5) with an acid or base (such as monobasic sodium phosphate and / or dibasic hydrogen phosphate, hydrochloric acid or sodium hydroxide). The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0145] Dosage, toxicity, and therapeutic efficacy of such subject smLNPs or compositions of the present disclosure can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example, to determine LD 50 (a dose lethal to 50% of the population) and ED 50 (the dose that is therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as the ratio LD 50 / ED 50Compounds that exhibit high therapeutic indices are preferred. While using compounds that exhibit toxic side effects, care should be taken to design delivery systems that target such compounds to the site of affected tissue in order to minimize potential damage to unaffected cells and thereby reduce side effects.

[0146] The data obtained from cell culture assays and animal studies can be used in formulating a dosage range for use in humans. The dosage of such compounds is preferably within the range that includes the ED 50 The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the methods of the present disclosure, the therapeutically effective dose can be estimated initially from cell culture assays. A dose is formulated in animal models to achieve an IC value of 1.5, 1.0, or 2.0 as determined in cell culture. 50 (i.e., the concentration of the test compound that achieves half-maximal inhibition of symptoms). Such information can be used to more accurately determine useful doses in humans. Levels in plasma are measured, for example, by high performance liquid chromatography.

[0147] As defined herein, a "therapeutically effective amount" (e.g., an effective dose) of the subject smLNP or composition of the present disclosure depends on the selected LNP or composition. For example, a single dose amount in the range of about 0.001 to 0.1 mg / kg of patient body weight may be administered; in some embodiments, about 0.005, 0.01, 0.05 mg / kg is administered. In some embodiments, 600,000 IU / kg is administered (IU can be determined by lymphocyte proliferation bioassay and expressed in international units (IU) established by the World Health Organization's first international standard for interleukin-2 (human)). The smLNP or composition may be administered once or more per day to once or more per week; including once every other day. The skilled artisan will appreciate that certain factors may affect the dosage and schedule required to effectively treat the subject, including but not limited to the severity of the disease or disorder, previous treatment, the subject's overall health and / or age, and other diseases present. In addition, treating a subject with a therapeutically effective amount of the subject smLNP or composition of the present disclosure may include a single treatment, or may include a series of treatments. In some embodiments, the composition is administered every 8 hours for 5 days, followed by a rest period of 2 to 14 days (eg, 9 days), followed by an additional 5 days of administration every 8 hours.

[0148] In some embodiments, the smLNP compositions are formulated for in vivo delivery. In some embodiments, the smLNP compositions are formulated for ex vivo delivery. The LNPs disclosed herein can be adsorbed onto almost any cell type that is mixed or contacted with them. Once adsorbed, the smLNPs can be endocytosed by some cells, exchange lipids with the cell membrane, or fuse with the cells. The transfer or incorporation of the nucleic acid molecule portion of the particle can occur via any of these approaches. Specifically, when fusion occurs, the particle membrane is integrated into the cell membrane, and the contents of the particle merge with the intracellular fluid.

[0149] In vivo administration

[0150] Systemic delivery of nucleic acid molecules encoding site-specific nucleases as described herein to distal target cells via a body system (such as circulation) in vivo can be achieved using the smLNP compositions disclosed herein. In addition, one or more nucleic acid molecules can be administered alone in the smLNP compositions disclosed herein, or in combination (e.g., co-administered) with one or more additional smLNP compositions comprising peptides, polypeptides, or small molecules (such as conventional drugs).

[0151] For in vivo administration, administration can be in any manner known in the art, such as by injection, oral administration, inhalation (e.g., intranasal or intratracheal), transdermal application, or rectal administration. In vivo administration can be accomplished via a single dose or divided doses. The smLNP composition can be administered parenterally, i.e., intraarticularly, intravenously, intraperitoneally, subcutaneously, or intramuscularly. In certain embodiments, the smLNP composition is administered intravenously or intraperitoneally by bolus injection. In certain embodiments, the smLNP composition of the present disclosure is administered parenterally or intraperitoneally. In addition or alternatively, the smLNP composition of the present disclosure, alone or in combination with other suitable components, can be made into an aerosol formulation (i.e., they can be "atomized") to be administered via inhalation (e.g., intranasal or intratracheal). Aerosol formulations can be placed in pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, etc.

[0152] Those skilled in the art will appreciate that the amount of particles administered will depend on the ratio of nucleic acid molecule to lipid, the specific nucleic acid molecule used, but will generally be between about 0.01 and about 50 mg / kg body weight, preferably between about 0.1 and about 5 mg / kg body weight, or about 10-10 particles per administration (e.g., injection).

[0153] Ex vivo administration

[0154] For ex vivo applications, the delivery of the smLNP compositions disclosed herein can be administered to any cell grown in culture. In some embodiments, the cell is an animal cell, more preferably a mammalian cell, and most preferably a human cell. When performed ex vivo, the contact between the cell and the smLNP occurs in a biocompatible medium. The concentration of the smLNP in the smLNP composition varies depending on the specific application, but is generally between about 1 μmol and about 10 mmol. Cells treated with smLNPs can generally be carried out at physiological temperature (about 37° C.) for a period of from about 1 to 72 hours, preferably from about 2 to about 5 hours, from about 2 to about 4 hours, or from about 1 to about 3 hours.

[0155] Site-specific endonucleases for gene shuffling

[0156] Gib11SpaCas9 is a synthetic RNA-guided endonuclease (RGEN) generated using homology-based gene family shuffling of CRISPR-Cas9 endonuclease sequence fragments from four different Staphylococcus species (Staphylococcus lugdunensis, Staphylococcus pasteuri, Staphylococcus microti, and Staphylococcus hyicus). Briefly, the sequences of all four Cas9 endonucleases were compared to identify regions with high homology to act as anchor points, thereby decomposing each of the Cas9 endonucleases into eight corresponding microdomains. A gene family shuffled synthetic Cas9 endonuclease library was prepared by randomly assigning each microdomain to be derived from one of the four original Cas9 endonucleases, except for the C-terminal microdomain that was selected as the PAM interaction (PI) domain from the Staphylococcus lugdunensis Cas9. The resulting library had a theoretical complexity of 8192. The library was initially screened for Cas9 endonuclease activity using a bacterial live / dead assay, and candidate synthetic Cas9 endonucleases were further screened in HEK cells using a BFP disruption assay. This led to the identification of Gib11Cas9 as a candidate synthetic Cas9 endonuclease with high Cas9 endonuclease activity. Gib11SpaCas9 was generated by replacing the C-terminal portion of Gib11Cas9 containing the PI domain with a polypeptide containing the PI domain from Staphylococcus pasteurianus.

[0157] F8Cas9 is a synthetic RNA-guided endonuclease (RGEN) produced using the following method: CRISPR-Cas9 endonuclease sequence fragments of four different Staphylococcus species (Staphylococcus lugdunensis, Staphylococcus pasteurianus, Staphylococcus microti, and Staphylococcus suis) were subjected to homology-based gene family shuffling. In short, the sequences of all four Cas9 endonucleases were compared to identify regions with high homology to act as anchor points, thereby decomposing each of the Cas9 endonucleases into 12 corresponding microdomains. The synthetic Cas9 endonuclease library of gene family shuffling was prepared in the following manner: each microdomain was randomly assigned to be derived from one of the four original Cas9 endonucleases, except for the C-terminal microdomain selected as the PAM interaction (PI) domain from Staphylococcus lugdunensis Cas9. The resulting library has 1.3x 10 5 The library was initially screened for Cas9 endonuclease activity using a bacterial live / dead assay, and candidate synthetic Cas9 endonucleases were further screened in HEK cells using a BFP disruption assay. This led to the identification of F8Cas9 as a candidate synthetic Cas9 endonuclease with high Cas9 endonuclease activity.

[0158] E2Cas9 is a synthetic RNA-guided endonuclease (RGEN) produced using the following method: CRISPR-Cas9 endonuclease sequence fragments of four different Staphylococcus species (Staphylococcus lugdunensis, Staphylococcus pasteurianus, Staphylococcus voles, and Staphylococcus suis) were subjected to homology-based gene family shuffling. In short, the sequences of all four Cas9 endonucleases were compared to identify regions with high homology to act as anchor points, thereby decomposing each of the Cas9 endonucleases into 8 corresponding microdomains. A synthetic Cas9 endonuclease library of gene family shuffling was prepared in the following manner: each microdomain was randomly assigned to be derived from one of the four original Cas9 endonucleases, except for the C-terminal microdomain selected as the PAM interaction (PI) domain from Staphylococcus lugdunensis Cas9. The resulting library has a theoretical complexity of 8192. The library was initially screened for Cas9 endonuclease activity using a bacterial live / dead assay, and candidate synthetic Cas9 endonucleases were further screened in HEK cells using a BFP disruption assay. This led to the identification of E2Cas9 as a candidate synthetic Cas9 endonuclease with high Cas9 endonuclease activity.

[0159] P2H12Cas9 is a synthetic RNA-guided endonuclease (RGEN) produced using the following method: CRISPR-Cas9 endonuclease sequence fragments of four different Staphylococcus species (Staphylococcus lugdunensis, Staphylococcus pasteurianus, Staphylococcus microti, and Staphylococcus suis) were subjected to homology-based gene family shuffling. In short, the sequences of all four Cas9 endonucleases were compared to identify regions with high homology to act as anchor points, thereby decomposing each of the Cas9 endonucleases into 8 corresponding microdomains. A synthetic Cas9 endonuclease library of gene family shuffling was prepared in the following manner: each microdomain was randomly assigned to be derived from one of the four original Cas9 endonucleases, except for the C-terminal microdomain selected as the PAM interaction (PI) domain from Staphylococcus lugdunensis Cas9. The resulting library has a theoretical complexity of 8192. The library was initially screened for Cas9 endonuclease activity using a bacterial live / dead assay, and candidate synthetic Cas9 endonucleases were further screened in HEK cells using a BFP disruption assay. This led to the identification of P2H12Cas9 as a candidate synthetic Cas9 endonuclease with high Cas9 endonuclease activity.

[0160] All publications and patent applications mentioned in this disclosure are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

[0161] No admission is made that any reference cited herein constitutes prior art. The discussion of the reference states the views advocated by its author, and the inventors reserve the right to challenge the accuracy and relevance of the cited documents. It should be clearly understood that although a number of sources of information are mentioned herein, including scientific journal articles, patent documents, and textbooks; this citation does not constitute an admission that any of these documents form part of the common general knowledge in the art.

[0162] The discussion of the general method given herein is intended for illustrative purposes only. Other alternative methods and alternatives will be clear to those skilled in the art after reviewing this disclosure, and are to be included in the spirit and scope of the present application.

[0163] Examples

[0164] Additional embodiments are disclosed in further detail in the following examples, which are provided by way of illustration only and are not intended to limit the scope of the disclosure or the claims in any way.

[0165] Example 1: General experimental procedure

[0166] The practice of the present disclosure will employ, unless otherwise indicated, techniques of molecular biology, microbiology, cell biology, biochemistry, nucleic acid chemistry, and immunology, which are known to those skilled in the art. Such techniques are explained in references such as the following: Molecular Cloning: A Laboratory Manual, 4th edition (Sambrook et al., 2012) and Molecular Cloning: A Laboratory Manual, 3rd edition (Sambrook and Russel, 2001) (collectively referred to herein as "Sambrook"); Current Protocols in Molecular Biology (FM Ausubel et al., eds., 1987, including supplements through 2014); PCR: The Polymerase Chain Reaction (Mullis et al., eds., 1994); Beaucage et al., eds., Current Protocols in Nucleic Acid Chemistry, John Wiley & Sons, Inc., New York, 2000 (including supplements through 2014); Gene Transfer and Expression in Mammalian Cells (Cell Signaling Technologies, Inc., New York, 2003); Cells [Gene transfer and expression in mammalian cells] (Makrides ed., Elsevier Sciences BV, Amsterdam, 2003); and Current Protocols in Immunology [Immunology laboratory manual] (Horgan K and S. Shaw (1994), including supplements until 2014). Unless otherwise stated, procedures involving the use of commercially available kits and reagents were generally performed according to the protocols and / or parameters defined by the manufacturer, as appropriate.

[0167] Example 2: Lipid-based nanoparticles containing mRNA encoding exemplary site-specific endonucleases Characterization

[0168] This example describes experiments performed to characterize the physical properties of exemplary LNP compositions according to some embodiments of the present disclosure. In these experiments, the particle size of eleven LNP compositions each containing an mRNA molecule encoding a site-directed endonuclease was evaluated and compared to a reference LNP composition containing an mRNA encoding SpCas9. Figures 1A-1E As shown in FIG. , the smCas9 mRNA-LNPs of the present disclosure were observed to have a slightly increased size ( Figure 1A Briefly, LNPs were diluted in PBS to a concentration of 1 μg / mL RNA and then serially diluted in 2-fold dilutions in 384-well plates. The samples were then analyzed for z-average measurements of particle diameter using a Wyatt DynaPro plate reader II.

[0169] It was also observed that some smCas9 mRNA-LNPs had increased mixed LNP population heterogeneity as determined by the polydispersity index (PDI), which indicated a more heterogeneous size population including some larger LNPs ( Figure 1B ). LNPs were diluted to 1 μg / mL RNA concentration in PBS and then serially diluted in 2-fold dilutions in 384-well plates. The samples were then analyzed for polydispersity measurements using a Wyatt DynaPro Plate Reader II.

[0170] In addition, the results of nanoparticle tracking analysis (NTA) indicated a more heterogeneous size distribution of smCas9GST3-K-LNPs when compared to the reference SpCas9-LNPs. NTA was performed by diluting the LNPs to an appropriate working concentration in PBS and then measuring the average particle size of the samples using a Malvern Nanosight instrument (see Figure 1C ). Further characterization of the distribution of particle to RNA ratios as a function of particle size was calculated by normalizing the LNP size as measured by NTA to the concentration of encapsulated RNA as determined by the Ribogreen assay, see Figure 1E Finally, if Figure 1D As shown in , no changes in the encapsulation efficiency of mRNA into LNPs were observed in these experiments. Encapsulation efficiency was determined by Ribogreen analysis using the Quant-iT Ribogreen RNA Assay Kit (Life Technologies Catalog No. R11490). In brief, LNPs were placed in X-100 (at 1% final dilution) to a concentration of 1 μg / mL. Ribogreen fluorescent dye (which is impermeable to LNPs) for measuring RNA content was then added to the samples and evaluated against an appropriate standard curve according to the manufacturer's recommendations. Encapsulation efficiency was calculated by subtracting the amount of RNA that was not present. The Ribogreen fluorescence signal in the sample with X-100 is The ratio of the fluorescence signal of the sample to that of the Ribogreen X-100.

[0171] In vitro testing of smCas9 variants in mRNA form

[0172] This example describes experiments performed to evaluate the in vitro editing efficiency of exemplary LNP compositions according to some embodiments of the present disclosure. In these experiments, the in vitro editing efficiency of six LNP compositions, each containing an mRNA molecule encoding a site-directed nuclease, was evaluated, and the in vitro editing efficiency was compared with a reference LNP composition containing SpCas9 encoding mRNA. The site-directed nucleases used in these experiments were Gib11Spa3, Gib11Spa1, Slu, F8, E2, and P2H12 (see Figure 2 ). In these experiments, mRNA was transfected into murine Hepa 1-6 cells using the commercially available system lipofectamine MessengerMax according to the manufacturer's instructions (ThermoFisher Scientific catalog number LMRNA003). The targeted locus is the albumin locus. The gRNA targeting the albumin gene used in all cell experiments shown is a 100-mer of the following sequence: 5'-ugcCAGUUCCCGAUCGUUACGUUUUAGUACUCUGGAAACAGAAUCUACUGAAACAAGACAAUAUGUCGUGUUUAUCCCAUCAAUUUAUUGGUGGGAUuuu-3' (SEQ ID NO: 50), where lowercase letters represent phosphorothioate linkages. Editing efficiency was calculated by cell lysis and genomic DNA extraction using Qiagen DNeasy blood and tissue kit (Cat. No. 69506), followed by PCR amplification of the targeted region of the albumin locus, sequencing, and TIDE analysis as described by Brinkman et al., Nucleic Acids Res. 2014 Dec 16;42(22):e168. The gene editing efficiency of the tested LNP compositions was observed to be comparable to that of the reference LNP compositions. Strikingly, at least two LNP compositions comprising the site-directed endonucleases Gib11Spa3 and Gib11Spa1 appeared to have significantly superior efficiency compared to the reference polypeptide SpCas9.

[0173] In vivo testing of smCas9 variants delivered as mRNA-LNPs

[0174] This example describes experiments conducted to evaluate the in vivo editing efficiency of exemplary LNP compositions according to some embodiments of the present disclosure in C57BL / 6 mice. In these experiments, the in vitro editing efficiency of two LNP compositions, each containing an mRNA molecule encoding a site-directed endonuclease, was evaluated and compared with a reference LNP composition containing SpCas9 encoding mRNA. The LNP compositions were administered intravenously as a single dose to C57BL / 6 mice at different doses. Figure 3 In, the dose is expressed as mg of encapsulated RNA / kg body weight, or "mpk". The locus targeted by this experiment is the albumin locus. It was observed that Gib11Spa3 had an editing efficiency significantly greater than SpCas9 when administered at a dose of 1.5mpk or 2mpk. In addition, it was observed that both doses (i.e., 1.5 and 2mpk) of Gib11Spa1 had an editing efficiency greater than that of SpCas9 at a dose of 2mpk. The editing efficiency of all mouse experiments was calculated by the following method: liver tissue homogenization and genomic DNA extraction were performed using the Qiagen DNeasy blood and tissue kit (Catalog No. 69506), followed by PCR amplification, sequencing, and TIDE analysis of the targeted region of the albumin locus, as described by Brinkman et al., Nucleic Acids Res. [Nucleic Acids Research] December 16, 2014; 42(22): e168.

[0175] Evaluation of mRNA sequences and chemical modifications

[0176] This example describes experiments performed to demonstrate the editing efficiency of exemplary LNP samples each containing mRNA molecules encoding the following site-specific endonucleases when administered intravenously in C57BL / 6 mice at a dose of 2 mpk: smCas9 GST3 (GST3 mRNA, SEQ ID NO: 34; GST3 polypeptide, SEQ ID NO: 35), smCas9 GST3-K (GST3-K mRNA, SEQ ID NO: 36; GST3-K polypeptide, SEQ ID NO: 37), smCas9 GST3-v1 (GST3-v1 mRNA, SEQ ID NO: 38; GST3-v1 polypeptide, SEQ ID NO: 39), smCas9 GST1-v1 (GST1-v1 mRNA, SEQ ID NO: 40; GST1-v1 polypeptide, SEQ ID NO: 41), or reference nuclease SpCas9. The target locus for these experiments was the albumin locus of C57BL / 6 mice. The gRNA targeting the albumin gene used in all in vivo mouse experiments shown was a 100-mer of the following sequence: 5'-ugcCAGUUCCCGAUCGUUACGUUUUAGUACUCUGGAAACAGAAUCUACUGAAACAAGACAAUAUGUCGUGUUUAUCCCAUCAAUUUAUUGGUGGGAUuuu-3' (SEQ ID NO: 50), where lowercase letters represent phosphorothioate linkages. The GST3 variant is the Gib11Spa3 variant described above. GST3-K is a Gib11Spa3 variant with a consensus Kozak consensus sequence. GST3-v1 is a Gib11Spa3 variant with SpCas9NLS (nuclear localization sequence) / linker. GST1-v1 is a Gib11Spa1 variant with SpCas9NLS / linker. See Figure 6 It was observed that all smCas9 variants tested performed better than SpCas9 in the mRNA-LNP format. The results also showed that variations in the Gib11Spa3 construct design did not appear to have a significant impact on functional performance. Figure 4 All experimental parameters used in these experiments were similar to those described above for the in vivo mouse testing.

[0177] This example further describes experiments demonstrating the effects of N1-methylpseudouridine base modification on smCas9 and SpCas9 mRNA on editing efficiency (as indicated by indel frequency) when delivered as mRNA-LNPs in vivo in C57BL / 6 mice via a single intravenous 2 mpk dose. Figure 5. All experimental parameters used in these experiments were similar to those described above for the in vivo mouse tests. Here, the mRNAs for SpCas9, smCas9 GST3-v1, and smCas9 GST1-v1 were modified with N1-methylpseudouridine bases, and the editing efficiency of LNPs containing these mRNAs was measured and compared to that of LNPs containing the same mRNA in unmodified form. The N1-methylpseudouridine base modification appears to have an effect only on the editing efficiency of SpCas9 mRNA-LNPs, where it leads to improved performance.

[0178] Improved LNP stability

[0179] This example describes an experiment performed to measure the number of mRNA-LNPs / mL solution before and after one week of storage at 2°C-8°C, where the mRNA encoded SpCas9 or a smCas9 variant. In this experiment, it was observed that while the number of mRNA-LNPs decreased significantly when the mRNA encoded SpCas9, no significant changes were observed for the other compositions (i.e., with mRNA encoding a smCas9 variant). Changes in LNP concentration indicate particle aggregation and fusion. See Figure 6 LNP concentrations were measured before and after 1 week of storage by NTA analysis of samples using a Malvern Nanosight instrument. Between measurements on day 1 and day 7, LNPs were stored at 2°C-8°C.

[0180] This example further describes experiments performed to visualize mRNA-LNPs when prepared with SpCas9 mRNA or smCas9 Gib11Spa3 mRNA by cryo-transmission electron microscopy (cryo-TEM). Figure 7 It was observed that LNPs carrying smCas9 mRNA presented less morphological irregularities compared to mRNA-LNPs carrying mRNA encoding SpCas9. Cryo-TEM analysis was performed by rapidly freezing the LNPs using a Semi-Cryoplunge 3 system and imaging on a JEOL 2100F 200 kV field emission electron microscope.

[0181] This example further describes experiments performed to measure the editing efficiency of mRNA-LNP formulations carrying mRNA encoding SpCas9 or the smCas9 variant Gib11Spa3 when injected intravenously in C57BL / 6 mice at a dose of 2 mpk 1 day or 9 days after the formulations were prepared and stored at 2°C-8°C (the same LNP batch was used in each group). Figure 8smCas9 as an mRNA payload was observed to produce more stable LNPs than SpCas9: an approximately 3.6-fold decrease in editing efficiency between formulations injected one and nine days after preparation was observed for SpCas9, whereas the decrease for smCas9 was only approximately 1.3-fold. All experimental parameters used in these experiments were similar to those described above for the in vivo mouse tests.

[0182] Example 3: Evaluation of LNPs in Methods of Treating Hemophilia A and Cardiovascular Disease

[0183] Applicants envision using the following animal models to evaluate the efficacy and safety of smCas9 mRNA LNPs: C57BL / 6 mice, HemA knockout mice, sprague Dawley rats, and cynomolgus monkeys. Without being bound by any particular theory, it is believed that smCas9 mRNA LNPs may be at least as effective as SpCas9 mRNA LNPs in all of these preclinical models.

[0184] In these experiments, smCas9 mRNA LNPs, particularly the Gib11Spal and Gib11Spa3 variants, can effectively produce gene editing at the albumin locus in C57BL / 6 mice. Additional experiments in this model include testing smCas9 mRNA in various types of LNP formulations, evaluating Slu, E2, F8, and P2H12 variants, evaluating the effects of base and sequence modifications on smCas9 mRNA effectiveness, evaluating dose response and multi-dose performance, and further evaluating smCas9 mRNA LNP function during stability testing.

[0185] Applicants also envision using HemA knockout mice to evaluate targeted integration of FVIII into the albumin locus; using Sprague Dawley rats to evaluate the safety of smCas9 mRNA LNPs by evaluating liver toxicity and immune responses; and using cynomolgus monkeys to evaluate gene editing efficacy, biodistribution, and safety. It is envisioned that guide sequence testing in primary human hepatocytes will be used to evaluate off-target effects of smCas9 mRNA LNPs.

[0186] LNP technology has a proven safety profile in the clinic, and it is believed that LNP formulations with smCas9 mRNA may have an improved therapeutic index compared to current LNP formulations with spCas9 mRNA. The clinical safety and efficacy of smCas9 mRNA LNPs can be evaluated, for example, by testing one or more of the following: serum clinical chemistry, CBC, neutralizing antibodies to Cas9 and LNPs, injection site inflammatory response, cytokine induction, and target biomarker activity.

[0187] Example 4: Evaluation of LNP compositions containing mRNA encoding smCas9 in non-human primate cells

[0188] To further evaluate the gene editing efficacy, biodistribution, and safety of the smCas9-mRNA-LNP formulations described in Examples 2 and 3, a cynomolgus monkey (cyno) model was used.

[0189] In these experiments, the smCas9-mRNA-LNP described herein, for example, in Examples 2 and 3, was formulated for administration. The formulation was administered to approximately 3kg male cynomolgus monkeys via intravenous (IV) infusion at a dose ranging from 1-2mg / kg. The safety issues of cynomolgus monkeys were subsequently monitored, euthanized within 8 days of receiving the infusion, and their liver and spleen gene editing, biodistribution, and tolerance readout were evaluated. It is expected that the LNP formulations of the delivery smCas9 mRNA that have been shown to achieve high editing efficiency in mice can perform equally well across species (such as non-human primate species). Without intending to be bound by any particular theory, it is believed that the delivery and stability advantages observed in the case of the smCas9-mRNA-LNP disclosed herein are not unique to a specific test model.

[0190] Example 5: In vivo safety of LNP compositions containing mRNA encoding smCas9 in rats

[0191] To evaluate the safety of exemplary smCas9-mRNA-LNP formulations according to some embodiments of the present disclosure, rat toxicity studies were performed.

[0192] In these experiments, rats were injected with 2 mg / kg of smCas9 GST1 mRNA-LNP or SpCas9 mRNA-LNP (n=3 for each condition), where the only difference between the LNP formulations was their nucleic acid components. Rats injected with SpCas9 mRNA-LNPs exhibited acute toxicity responses, with no survival observed in the group within 12 hours of dosing. In contrast, rats injected with smCas9 GST1 mRNA-LNPs exhibited improved tolerance, as demonstrated by the termination of the study on the 7th day after injection, as all rats in this group survived. Given the rapid onset of toxicity observed in the case of SpCas9 mRNA-LNPs, this is unlikely to be due to any effects of the genome editing of the LNPs, and it is expected that any of these effects will take longer than 12 hours to manifest. These results indicate that for other similarly formulated LNPs, LNPs containing smCas9 mRNA are less toxic than LNPs containing larger SpCas9 mRNAs. These results are surprising because the lipid to mRNA weight ratio in many smCas9-mRNA-LNPs was found to be greater than that in the corresponding SpCas9-mRNA-LNPs, and total LNP lipid content is considered a driver of LNP toxicity.

[0193] Example 6: In vivo editing efficiency of LNP compositions containing mRNA with various base modifications

[0194] To further evaluate the effects of different base modifications on smCas9 and SpCas9 mRNA-LNPs, in vivo indel analysis in mice was performed.

[0195] C57BL / 6 mice were injected with a single dose of 1 mg / kg of one of the following mRNA-LNPs: Gib11Spa3(N1-methylpseudouridine; Uridine depletion / codon optimization) and Gib11Spa1 (unmodified, N1-methylpseudouridine, pseudouridine, or 5-methoxyuridine; with or without Uridine depletion / codon optimization). LNP contains one of the following two different gRNAs targeting different loci in the mouse genome: gRNA T1 (all modifications) or gRNA T2 (only N1-methyl pseudouridine modification). The results of indel frequency are shown in Table 1. When mRNA is depleted of uridine and codon optimized, most Gib11Spa1 mRNA-LNPs show improved editing efficiency. Compared with unmodified conditions, pseudouridine modification leads to improved editing efficiency of Gib11Spa1 mRNA-LNP, but this effect is reduced when mRNA is depleted of uridine and codon optimized. In contrast, 5-methoxyuridine leads to reduced editing efficiency of Gib11Spa1 mRNA-LNP with and without uridine depletion and codon optimization.

[0196] Table 1

[0197]

[0198] While particular alternatives of the present disclosure have been disclosed, it should be understood that various modifications and combinations are possible and are contemplated within the true spirit and scope of the appended claims.Therefore, there is no intention to be limited to the precise abstract and disclosure presented herein.

[0199] Sequence Listing

[0200]

[0201]

[0202]

[0203]

[0204]

[0205]

[0206]

[0207]

[0208]

[0209]

[0210]

[0211]

[0212]

[0213]

[0214]

[0215]

[0216]

[0217]

[0218]

[0219]

[0220]

[0221]

[0222]

[0223]

[0224]

[0225]

[0226]

Claims

1. A lipid-based nanoparticle (LNP) composition, the lipid-based nanoparticle composition comprising: A nucleic acid molecule comprising a nucleotide sequence encoding a synthetic RNA-guided endonuclease; and One or more lipid moieties, the one or more lipid moieties being selected from the group consisting of composition: Ionizable lipids, neutral lipids, PEG lipids, and cholesterol; wherein the length of the nucleic acid molecule is less than 3.8 kb; and wherein the synthetic RNA-guided endonuclease comprises fragments of RNA-guided endonucleases from at least two bacterial species, and Wherein the synthetic RNA-guided nuclease consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4 and SEQ ID NO 5.

2. The LNP composition of claim 1, wherein the length of the nucleic acid molecule is less than 3.7 kb.

3. The LNP composition of claim 1 or 2, wherein the length of the nucleic acid molecule is less than 3.5 kb.

4. The LNP composition of claim 1 or 2, wherein the nucleic acid molecule is messenger RNA.

5. The LNP composition of claim 1 or 2, wherein the bacterial species is selected from Staphylococcus lugdunensis, Staphylococcus pasteurianus, Staphylococcus microti and Staphylococcus hyosus.

6. The LNP composition of claim 1 or 2, wherein the synthetic RNA-guided endonuclease comprises a PAM interaction domain from Staphylococcus lugdunensis or Staphylococcus pasteurianus.

7. The LNP composition of claim 1 or 2, wherein the nucleotide sequence encoding the synthetic RNA-guided endonuclease is operably linked to at least one additional nucleotide sequence.

8. The LNP composition of claim 7, wherein the at least one additional nucleotide sequence comprises an untranslated terminal region, a consensus Kozak signal, a nucleotide sequence encoding a nuclear localization signal selected from a nucleoplasmin NLS or an SV40 NLS, a nucleotide sequence encoding a linker peptide, a nucleotide sequence encoding a tag peptide, or any combination thereof.

9. The LNP composition of claim 1 or 2, wherein the synthetic RNA-guided endonuclease is a Cas9 protein.

10. The LNP compositions of claim 1 or 2, wherein the nucleic acid molecule is composed of a nucleotide sequence selected from the group consisting of composition: SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:

11.

11. The LNP composition of claim 1 or 2, wherein the nucleotide sequence is codon optimized for expression in a host cell.

12. The LNP composition of claim 11, wherein the host cell is a human cell, a murine cell, or a non-human primate (NHP) cell.

13. The LNP composition of claim 1 or 2, further comprising a guide RNA (gRNA) or a nucleic acid encoding the gRNA.

14. The LNP composition of claim 1 or 2, wherein the LNPs of the LNP composition comprise C12-200, cholesterol, DOPE, PEG-DMPE, or any combination thereof.

15. The LNP composition of claim 1 or 2, wherein the LNPs of the LNP composition have a lower rate of change of physicochemical properties than LNPs of a reference LNP composition comprising a nucleic acid molecule comprising a nucleotide sequence encoding a synthetic RNA-guided endonuclease, wherein the nucleic acid molecule is greater than 4 kb.

16. The LNP composition of claim 15, wherein the LNPs of the LNP composition have a rate of change of a physicochemical property that is at least 5% less than the corresponding rate of the LNPs of the reference LNP composition.

17. The LNP composition of claim 1 or 2, wherein the LNP composition has a lower rate of decrease in functional performance compared to a rate of decrease in functional performance of a reference LNP composition comprising a nucleic acid molecule comprising a nucleotide sequence encoding a synthetic RNA-guided endonuclease, wherein the nucleic acid molecule is greater than 4 kb.

18. The LNP composition of claim 17, wherein the LNP composition has a rate of functional property degradation that is at least 5% less than the corresponding rate of the reference LNP composition.

19. The LNP composition of claim 1 or 2, wherein the LNPs of the LNP composition have an average particle diameter greater than the average particle diameter of LNPs of a reference LNP composition comprising a nucleic acid molecule comprising a nucleotide sequence encoding a synthetic RNA-guided endonuclease, wherein the nucleic acid molecule is greater than 4.0 kb.

20. The LNP composition of claim 19, wherein the LNPs of the LNP composition have an average particle diameter at least 10% larger than the average particle diameter of the LNPs in the reference LNP composition.

21. The LNP composition of claim 1, wherein the one or more lipid moieties are amino lipids.

22. Use of an LNP composition in the preparation of a medicament for delivering a nucleic acid molecule to a cell, wherein the delivering the nucleic acid molecule to the cell comprises contacting the cell with the LNP composition according to claim 1 or 2, wherein the LNP composition comprises the nucleic acid molecule.

23. Use of an LNP composition in the preparation of a drug for editing the genome of a cell, wherein editing the genome of a cell comprises providing the cell with the LNP composition according to claim 1 or 2.

24. The use of claim 23, wherein the editing efficiency of the LNP composition is greater than the editing efficiency of a reference LNP composition, the reference LNP composition comprising a nucleic acid molecule comprising a nucleotide sequence encoding a site-specific endonuclease, wherein the nucleic acid molecule is greater than 4 kb.

25. The use of claim 24, wherein the editing efficiency of the LNP composition is at least 5% greater than the editing efficiency of the reference LNP composition.

26. The use of claim 22, wherein the cell is a human cell, a mouse cell, or a non-human primate cell.